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(57) ABSTRACT 
A method of treating a neurological condition in a patient, 
the method including the step of applying an electrical 
stimulation from conductors to the patient's head at a 
stimulation application site. In some embodiments, the elec 
trical stimulation includes a composite electrical signal 
further comprising at least one signal form configured to 
provide long-term treatment of the neurological condition 
and at least one signal form configured to provide analgesia 
for short-term pain relief. The invention also provides an 
electrical stimulation apparatus having an electrical signal 
generator adapted to provide an electrical signal form con 
figured to provide long-term treatment of a neurological 
condition and to provide an electrical signal form configured 
to provide analgesia for short-term pain relief. 
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Apparatus for providing an electrical signal form for 
long-term treatment of a neurological condition 
Apparatus for providing an electrical signal form to 
provide analgesia for short-term pain relief 
Fig. 3 
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METHODS AND APPARATUS FOR 
ELECTRICAL STIMULATION 
INCORPORATION BY REFERENCE 
0001 All publications and patent applications mentioned 
in this specification are herein incorporated by reference to 
the same extent as if each individual publication or patent 
application was specifically and individually indicated to be 
incorporated by reference. 
FIELD 
0002 The present invention relates generally to methods 
and apparatus for electrically stimulating a tissue. More 
specifically, the present invention relates to methods and 
apparatuses for using electrical stimulation to treat fibro 
myalgia and other neurological conditions involving central 
pain, central sensitivity and abnormal brain neural network 
connectivity. 
BACKGROUND 
0003 Electrical stimulation is known to alter the activity 
of the brain and modulate neurotransmitter activity, both of 
which are capable of providing therapeutic effects in both 
nociceptive pain conditions and central pain conditions. The 
use of electrical stimulation to treat pain and other neuro 
logical conditions is described in U.S. Pat. No. 7,715,910; 
U.S. Pat. No. 8,494,625; US Patent Publ. No. 2011/ 
0307029; and WO 2013/169838. The disclosures of these 
publications are incorporated herein by reference. 
0004 Nociceptive pain is known to arise from stimula 
tion of peripheral nerve endings. The peripheral nociceptive 
signal is transmitted through the spinal cord to the brain, 
where it is processed through numerous pain-processing 
networks. Descending pathways from the brain to the spinal 
cord Subsequently modulate pain signals, thereby increasing 
or decreasing pain perception. 
0005. However, it is also known that enhanced activation 
of central pain-processing pathways and networks, through 
mechanisms such as neuroplastic changes in central neu 
ronal activity and neural network connectivity, can lead to 
spontaneous pain in the absence of peripheral nociceptive 
input. When this occurs, pain is said to have “centralized'. 
which results in lower pain thresholds, secondary hyperal 
gesia in uninjured areas, and Sustained pain potentiation. 
Brain-related centralized pain is thought to play a prominent 
role in chronic pain conditions. 
0006 Centralized pain is generally thought of as an 
outcome of central sensitivity (CS), which is also known as 
central sensitization, central augmentation, and central 
hypersensitivity among other terms. CS mechanisms in the 
brain have been implicated in the pathology of allodynia, 
which is the term used to describe a condition where pain is 
caused by a stimulus that does not normally provoke pain. 
CS mechanisms in the brain have also been implicated in 
hyperalgesia, which is the term used to describe a condition 
in which pain perceived from a stimulus is greater than what 
would normally be expected from that stimulus. Put simply, 
in central sensitivity the brain magnifies painful stimuli and 
eventually magnifies even associated non-painful stimuli. As 
pointed out in Latremoliere and Woolfe (1), because CS 
results from changes in the properties of neurons in the 
central nervous system, the pain is no longer coupled, as 
acute nociceptive pain is, to the presence, intensity, or 
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duration of noxious peripheral stimuli arising from both 
neuropathic and inflammatory sources. Further, in chronic 
pain conditions the increased excitability caused by CS far 
outlasts the initiating noxious stimulus, that is, the nocice 
ptive input that causes the pain to occur in the first place. 
0007. Before CS was discovered, typically only two 
models of pain were contemplated. The first is the afore 
mentioned nociceptive pain model, by which specific pain 
pathways are activated by peripheral pain stimuli, and the 
amplitude and duration of the pain experienced is deter 
mined entirely by the intensity and timing of the peripheral 
pain inputs. The second model contemplates gate controls in 
the central nervous system that open and close, thus enabling 
or preventing pain. Medical Science now recognizes CS as 
a third and unique model that contemplates neuroplastic 
changes in the functional properties and network connec 
tivity of the central nervous system. For example, the level 
of resting brain activity within multiple networks (e.g., 
functional network connectivity and effective network con 
nectivity) is now known to be associated with spontaneous 
pain in patients having centralized pain (2, 3). CS leads to 
reductions in pain threshold, increases in the magnitude and 
duration of responses to noxious input, and permits normally 
innocuous inputs to generate pain sensations. In addition, CS 
is also believed to be relevant in Somatic symptoms asso 
ciated with painful conditions, including but not limited to 
fatigue and sleep disorders. 
0008. The brain's role in CS is being increasingly 
revealed and understood in neuroscience, due in large part to 
the advent of functional brain imaging technologies. For 
example, Lee et al. (4) used functional magnetic resonance 
imaging (fMRI) to examine the extent to which brain 
activity contributes to the maintenance of CS in humans. 
When the intensity of pain during CS was matched to the 
intensity of pain during normal states, activity within the 
brainstem, including the mesencephalic pontine reticular 
formation and the anterior thalami, remained at an increased 
level during CS. Regarding brain areas related to the con 
sequence of increased pain perception during CS, cortical 
activity, mainly in the primary somatosensory area, has been 
significantly correlated with the intensity of pain attributable 
to both the force of noxious stimulation used, and the state 
in which noxious stimulation was applied. 
0009 Borsook et al. (5) reviewed the literature on brain 
activity using neuroimaging technologies. Their review 
details evidence of alterations in multiple sub-cortical and 
cortical processing mechanisms. Those alterations include 
sensory, emotional/affective, cognitive, and modulatory sys 
tems that are present in chronic pain. The authors note these 
findings provide evidence that increases understanding of 
the importance of the role of numerous brain regions in the 
centralization of pain and the contributions of those regions 
to the altered brain states associated with chronic pain 
conditions. Similarly, Schweinhardt and Bushnell (6) 
reviewed neuroimaging evidence of the active and enhanced 
modulatory role that the brain plays in pain processing in 
chronic pain patients. Schweinhardt and Bushnell also cite 
findings that brain activations in chronic pain involve brain 
circuitry not normally activated by acute nociceptive pain. 
0010 Because of this emerging understanding, the role of 
CS is increasingly being shown to be pathological in seem 
ingly unrelated chronic pain conditions and syndromes 
including fibromyalgia, complex regional pain syndrome, 
phantom pain, and migraine headaches. Yunus (7) identifies 
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no less than 14 common syndromes that lack structural 
pathology yet have CS as a common mechanism. These 
conditions further include chronic fatigue syndrome, irri 
table bowel syndrome, tension-type headaches, temporo 
mandibular disorder, myofascial pain syndrome, regional 
soft-tissue pain syndrome, restless leg syndrome, periodic 
limb movements in sleep, multiple chemical sensitivity, 
primary dysmenorrhea, female urethral syndrome, intersti 
tial cystitis, and post-traumatic stress disorder. Yunus also 
notes that CS may play a significant role in the pain 
associated with depression and in Gulf War Syndrome. 
0011 Giesecke et al. (8) used fMRI to demonstrate 
augmented central pain processing in patients with idio 
pathic chronic low back pain and fibromyalgia. Indeed, 
when equal levels of mechanical pressure intended to elicit 
a painful response were applied to patients and to normal 
controls, patients with chronic low back pain and fibromyal 
gia experienced significantly more pain and showed more 
extensive, common patterns of neuronal activation in pain 
related cortical areas of the brain than did the controls. Thus, 
CS may play an important role in persons with chronic low 
back pain that persists without identifiable physical pathol 
Ogy. 
0012. The role of CS in persistent inflammatory condi 
tions is also gaining recognition. In Gwilym et al. (9), fMRI 
illustrated significantly greater brain activation in osteoar 
thritis (OA) patients in response to stimulation of their 
referred pain areas (i.e., areas where pain persists but do not 
exhibit OA or related inflammation) compared with healthy 
controls, and the magnitude of this activation positively 
correlated with the extent of neuropathic-like elements to the 
patient’s pain. The role of CS in osteoarthritis has been the 
subject of several other investigations (10, 11, 12). As 
detailed in Imamura et al. (13), the refractory, disabling pain 
associated with knee OA is usually treated with total knee 
replacement. However, a comparison of OA patients with 
healthy normal controls showed patients with knee OA had 
significantly lower pressure pain thresholds (PPT) over 
widespread evaluated structures beyond the knee. The lower 
PPT values were correlated with higher pain intensity, 
higher disability scores, and with poorer quality of life. This 
Suggests that pain in these patients might be more associated 
with CS than with peripheral inflammation and injury. As the 
authors point out, the implications of the role of CS, and its 
potential for modulation, may provide exciting and innova 
tive cost effective therapeutic tools to control pain, reduce 
disability, and improve quality of life in knee OA patients. 
0013 Yet, the treatment of CS is a challenging task. As 
stated by Latremoliere and Woolfe (1), “The complexity is 
daunting because the essence of central sensitization is a 
constantly changing mosaic of alterations in membrane 
excitability, reductions in inhibitory transmission, and 
increases in Synaptic efficacy, mediated by many converging 
and diverging molecular players on a background of phe 
notypic Switches and structural alterations. Some centrally 
acting pharmaceutical agents such as gabapentin (14.15), 
ketamine (16), propofol (17) and anti-tumor necrosis factor 
alpha (TNF-alpha) therapy (18), just to name a few, have 
evidence of efficacy in treating CS. The patent literature has 
examples in the art of pharmaceutical use as a therapeutic 
agent for treating CS. For example, the use of dimiracetam 
for treatment of hyperalgesia and allodynia caused by cen 
tral sensitization in chronic pain has been taught. Further, the 
use of compounds associated with (R)-2-acetamido-N-ben 
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Zyl-3-methoxypropionamide has been taught to treat central 
neuropathic pain, including “neurological disorders charac 
terized by persistence of pain and hypersensitivity in a body 
region.” 
0014) Another relevant consideration is that analyses of 
numerous brain imaging and functional measures, including 
electroencephalographic (EEG) measures (19), have been 
shown to produce measures related to brain networks and 
functional connectivity that correlate to findings produced 
by fMRI imaging (20). Thus, the presence of brain activity 
associated with CS, and hence centralized pain, can be 
determined using EEG measures and analysis. 
0015. In addition to abnormalities in brain neural network 
connectivity, it is also known that a number of neurotrans 
mitters are involved in the processing of both central pain 
and nociceptive pain. In some cases, certain neurotransmit 
ters augment the processing of pain and are therefore 
associated with increased pain. In other cases, certain neu 
rotransmitters reduce the processing of pain, and are there 
fore associated with decreased pain. 
0016. The following citations are incorporated by refer 
ence in their entirety: 
00.17 1. “Central sensitization: a generator of pain hyper 
sensitivity by central neural plasticity'. Latremoliere A, 
Woolf C.J. J. Pain. 2009 September; 10(9):895-926. 
0018 2. “Intrinsic brain connectivity in fibromyalgia is 
associated with chronic pain intensity”. Napadow V. 
LaCount L. Park K, As-Sanie S, Clauw DJ, Harris R. E. 
Arthritis Rheum. 2010 August: 62(8):2545-55. 
0019. 3. “Disrupted functional connectivity of the pain 
network in fibromyalgia”, Cifre I, Sitges C, Fraiman D, 
Muñoz M A. Balenzuela P. González-Roldán A, Marti 
nez-Jauand M. Birbaumer N. Chialvo DR, Montoya P. 
Psychosom Med. 2012 January: 74(1):55-62. 
0020 4. “Identifying brain activity specifically related to 
the maintenance and perceptual consequence of central 
sensitization in humans', Lee MC, Zambreanu L, Menon 
D K, Tracey I. J Neurosci. 2008 Nov. 5; 28(45): 1142-9. 
0021 5. “A key role of the basal ganglia in pain and 
analgesia—insights gained through human functional 
imaging, Borsook D, Upadhyay J, Chudler E. H. Becerra 
L. Mol Pain. 2010 May 13: 6:27. 
0022 6. “Pain imaging in health and disease—how far 
have we come?”, Schweinhardt P. Bushnell M. C. J. Clin 
Invest. 2010 Nov. 1; 15(11):3788-97. 
0023 7. “Fibromyalgia and overlapping disorders: the 
unifying concept of central sensitivity syndromes”. Yunus 
MB. Semin Arthritis Rheum. 2007 June; 36(6):339-56. 
0024 8. “Evidence of augmented central pain processing 
in idiopathic chronic low back pain'. Giesecke T. Gracely 
RH, Grant MA, Nachemson A, Petzke F. Williams DA, 
Clauw DJ. Arthritis Rheum. 2004 February; 50(2): 613 
23. 
0025 9. “Psychophysical and functional imaging evi 
dence Supporting the presence of central sensitization in a 
cohort of osteoarthritis patients', Gwilym S. E. Keltner J 
R, Warnaby CE, Can AJ, Chizh B, Chessell I, Tracey I. 
Arthritis Rheum. 2009 Sep. 15: 61 (9):176-34. 
0026 10. “Lessons from fibromyalgia: abnormal pain 
sensitivity in knee osteoarthritis, Bradley L. A. Kersh B 
C, DeBerry J. J. Deutsch G, Alarcón G. A. McLain D A. 
Novartis Found Symp. 2004; 260:258-70. 
0027 11. “Sensitization in patients with painful knee 
osteoarthritis', Arendt-Nielsen L, Nie H, Laursen M B, 
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Laursen B. S. Madeleine P. Simonsen O H, Graven 
Nielsen T. Pain. 2010 June; 149(3):573-81. 
0028 12. “Pain mechanisms in osteoarthritis: under 
standing the role of central pain and current approaches to 
its treatment'. Mease PJ. Hanna S, Frakes E. P. Altman R 
D. J Rheumatol. 2011 August; 38(8): 1546-51. 
0029, 13. “Impact of nervous system hyperalgesia on 
pain, disability, and quality of life in patients with knee 
osteoarthritis: a controlled analysis”. Imamura M. 
Imamura S. T. Kaziyama H. H. Targino RA, Hsing W T. 
de Souza L. P. Cutait M M, Fregni F, Camanho G L. 
Arthritis Rheum. 2008 Oct. 15: 59(10): 1424-31. 
0030) 14. “Pharmacological modulation of pain-related 
brain activity during normal and central sensitization 
states in humans', Iannetti G. D., Zambreanu L, Wise RG, 
Buchanan T.J. Huggins J P Smart T. S. Vennart W. Tracey 
I. Proc Natl AcadSci USA. 2005 Dec. 13; 102(50): 18195 
2OO. 
0031) 15. “Chronic oral gabapentin reduces elements of 
central sensitization in human experimental hyperalge 
sia'. Gottrup H, Juhl G. Kristensen AD, Lai R, Chizh B 
A, Brown J. Bach F W. Jensen TS. Anesthesiology. 2004 
December: 101(6):350-8. 
0032) 16. “Pharmacodynamic profiles of ketamine (R)- 
and (S)- with 5-day inpatient infusion for the treatment of 
complex regional pain syndrome', Goldberg ME, Tori 
man MC, Schwartzman RJ, Mager DE, Wainer I W. Pain 
Physician. 2010 July; 13(4):379-87. 
0033 17. “Analgesic and antihyperalgesic properties of 
propofol in a human pain model, Bandschapp O. Filitz, J. 
Ihmsen H. Berset A, Urwyler A, Koppert W. Ruppen W. 
Anesthesiology. 2010 August; 8(2):421-8. 
0034. 18. “TNF-alpha and neuropathic pain—a review”. 
Leung L, Cahill C M. J Neuroinflammation. 2010 Apr. 16; 
7:27. 
0035. 19. “Functional connectivity: the principal-compo 
nent analysis of large (PET) data sets, Friston KJ, Frith 
CD, Liddle P F, Frackowiak R. S. J. Cereb Blood Flow 
Metab 1993: 13:5-14. 
0036 20. “Electrophysiological signatures of resting 
state networks in the human brain'. Mantini D, Perrucci 
MG, Del Gratta C, Romani G. L., Corbetta M. Proc Natl 
Acad Sci USA. 2007 Aug. 7: 104(32):2670-5. 
SUMMARY OF THE DISCLOSURE 
0037. The use of amplitude-modulated, pulse-width 
modulation signals to treat neurological dysfunction via 
stimulation of the brain is described, e.g., in U.S. Pat. No. 
7.715,910. Clinical tests have shown that specific electrical 
stimulation parameters—including waveform parameters, 
treatment protocols and stimulation sites—can provide sig 
nificant therapy benefits. These discoveries have also led to 
the development of stimulation systems particularly Suited 
to providing efficacious electrical stimulation therapy. 
0038. In the following description of the disclosed meth 
ods and apparatus, the term "centralized pain' is intended to 
mean any form of pain, whether chronic or acute, that is 
enhanced in its characteristics; Such as magnitude, duration 
and scope; due to abnormal brain activity associated with 
pain processing, or abnormalities involving neurotransmit 
ters associated with pain. Such brain activity may include, 
but is not limited to, central sensitivity and network con 
nectivity. Such neurotransmitters may include, but are not 
limited to, serotonin, norepinephrine, glutamate, N-Methyl 
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D-aspartic acid, Substance P, gama-aminobutyric acid, vari 
ous nucleotides and dopamine. 
0039. The term “central sensitivity” is intended to mean 
any central nervous system condition pathologically related 
to hyperalgesia, allodynia, reductions in pain threshold, 
increases in the magnitude and duration of responses to 
noxious input, results in normally innocuous inputs to gen 
erate pain sensations, or results in non-painful symptoms 
associated with increases in central nervous system respon 
siveness. Central sensitivity is also known by alternate terms 
that include but are not limited to “central sensitization', 
“central pain', 'central augmentation,” and “central hyper 
sensitivity”. 
0040. The terms “network connections” and “network 
connectivity” are intended to mean various forms of rela 
tionships between neural networks in brain regions involved 
in processing of information Such as pain. For example, 
“functional connectivity” refers to a statistical correlation 
between the activities of different brain regions. “Effective 
connectivity” denotes not simply a statistical but a causal 
influence between two brain regions. 
0041. The terms “treat” or “treating” are intended to 
mean the act of reducing, making less severe, mitigating, 
alleviating, or eliminating a condition and/or its symptoms 
for any period of time. 
0042 Except where the context requires otherwise, the 
term “comprise' and variations of the term, such as “com 
prising”, “comprises” and “comprised are not intended to 
be exclusive. Where, for example, a form of the word 
“comprise' is used to refer to one or more additives, 
components, integers or steps; its use is not intended to 
exclude other additives, components, integers or steps. 
0043. The term “stimulating is intended to mean the 
transmitting of any energy signal generated by a stimulation 
device. Such as an electrical stimulator, to the brain of a 
Subject for the purpose of influencing any function or 
physiological state of the Subjects brain that is at least one 
part of a pathway of pain; or for the purpose of influencing 
at least one neurotransmitter associated with pain. 
0044) The term “stimulation signal' is intended to mean 
any energy signal used in the process of stimulating a tissue 
Such as a brain. Other terms used to refer to Such a signal 
may include but are not limited to "cranial neurostimula 
tion”, “cortical stimulation”, “neuromodulation' and “neu 
rostimulation'. 
0045. The term “nociceptive pain' is intended to mean 
any pain arising from Stimulation of peripheral nerve end 
ings. 
0046. The term “conductor” is intended to include any 
electrical conduction pathway apparatus, such as electrical 
leads comprising wires, between an apparatus for providing 
electrical stimulation and a tissue to be stimulated. The term 
“conductor also includes an electrode or any other termi 
nating feature at the end of a conduction pathway apparatus 
configured to interface to the tissue to be stimulated. 
0047. The term “waveshape' is intended to mean an 
electrical signal waveform that may be approximated by an 
amplitude envelope resulting from the peaks of an amplitude 
modulated pulse train. 
0048. The term “analgesia’ is intended to mean any 
reduction or elimination in the amount, intensity, duration, 
location, form of, or perception of pain. 
0049. The term “rest' is intended to mean periods of time 
which are part of therapy and in which a patient is in a state 
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of preparedness to receive an electrical stimulation signal, 
but no signal is actually being delivered to the patient. 
0050. The electrical stimulation signal forms taught 
herein have been studied in clinical trials involving patients 
with fibromyalgia. Clinical data arising from these studies 
have demonstrated symptom improvement and evidence 
that central nervous system pain processing mechanisms are 
modified. Thus, the approach may hold promise for the 
treatment of numerous chronic pain states where abnormal 
central pain processing mechanisms are involved. 
0051. A method is taught for treating a neurological 
condition in a patient. Such neurological conditions may 
include, but are not limited to, fibromyalgia, hyperalgesia, 
central pain, central sensitivity, chronic pain, abnormal brain 
network connectivity, neuropathic pain, central pain arising 
from chronic osteoarthritis, central pain arising from chronic 
back pain, chronic headache, migraine headache or depres 
S1O. 
0052. The method may include the step of applying an 
electrical stimulation signal from conductors to the patients 
head at a stimulation application site. The electrical stimu 
lation signal may include a tissue transmission component 
and a therapeutic component. The method may also include 
the step of sequencing the electrical stimulation signal in 
bursts. One Such sequence may include at least two burst 
periods with at least one rest period in between each pair of 
bursts in which no stimulation is provided. In the method, 
the electrical stimulation signal may be subthreshold for 
detection by the patient. Further, the tissue transmission 
component may include a pulse train that has pulse frequen 
cies Sufficient to reduce tissue impedance between the con 
ductors and the patient’s brain. In one embodiment, the 
pulse train amplitude may have a minimum value of 0 Volts 
and a maximum value of 1 volt. In another embodiment, the 
pulse train amplitude may have a maximum value of 0.2 
Volts. In another embodiment, the pulse train frequency is 
between 10,000 Hz and 20,000 Hz. In another embodiment, 
the pulse train frequency is approximately 15,000 Hz. The 
pulse train may also be monopolar. 
0053. Further to the method, the pulse train may be pulse 
width modulated to create a variable duty cycle of on time 
and off time. In one embodiment, the pulse train duty cycle 
may be between 20% and 60%. In another embodiment, the 
pulse train duty cycle may be approximately 37.5%. Further 
still, the pulse train may be amplitude modulated to create a 
waveshape which may include an amplitude envelope. Such 
waveshapes may include those that are formed to create a 
therapeutic component. In one embodiment, the amplitude 
envelope may form a rectangular wave. In another embodi 
ment, the amplitude envelope may form a sinusoidal wave. 
In another embodiment, the amplitude envelope may form a 
composite of multiple sinusoidal waves. In one embodi 
ment, the waveshape may have a frequency between 1 HZ 
and 30 Hz. In another embodiment, the waveshape may have 
a frequency between 7 Hz and 12 Hz. 
0054. In another embodiment, the waveshape is a rect 
angular wave with frequencies ranging from 7 Hz to 12 HZ 
as a function of time. In another embodiment, multiple 
sinusoidal waves may have individual frequencies between 
1 Hz and 30 Hz. Further to the method, the frequency of the 
waveshape may change as a function of stimulation delivery 
time. 
0055. In one embodiment of the method, a pulse train 
may have amplitude with minimum value of 0 volts and 
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maximum value of 0.2 volts, a frequency of approximately 
15,000 Hz, and a duty cycle of approximately 37.5%. 
0056 Further to the method, stimulation may be applied 
in bursts with periods of time ranging from 1 second to 5 
minutes. In one embodiment, each burst period may range in 
time from 30 seconds to 2 minutes. Further still, each rest 
period may range in time from 1 second to 5 minutes. In one 
embodiment, each rest period may be 60 seconds. 
0057. Further still to the method, the patient’s electroen 
cephalogram (EEG) signal may be measured, including 
times when EEG may be measured during a rest period. In 
one embodiment, the EEG may be measured at the stimu 
lation application site. In another embodiment, the patients 
EEG signal may be measured during a period of rest prior to 
a first burst of stimulation signal. In an embodiment, Such 
periods of rest prior to a first burst may range in time from 
1 second to 5 minutes. In another embodiment, such period 
of rest prior to a first burst may be 3 minutes. 
0058. Further still to the method, the patient's EEG signal 
may be measured during a period of rest after a final burst 
of stimulation signal. In an embodiment, Such periods of rest 
after a final burst may range in time from 1 second to 5 
minutes. In another embodiment, such period of rest after a 
final burst may be 3 minutes. 
0059. Further still to the method, the sequencing step 
may include a burst and rest time sequence consisting of a 
first three minute period of rest; then applying a first burst of 
the electrical stimulation signal for 30 seconds; then after 
applying the first burst, ceasing application of the electrical 
stimulation signal for a second period of rest lasting 60 
seconds; then after the second period of rest, applying a 
second burst of the electrical stimulation signal for 60 
seconds; then after applying the second burst, ceasing appli 
cation of the electrical stimulation signal for a third period 
of rest lasting 60 seconds; then after the third period of rest, 
applying a third burst of the electrical stimulation signal for 
90 seconds; and then after applying the third burst, ceasing 
application of the electrical stimulation signal for a fourth 
period of rest lasting three minutes. In the embodiments, the 
stimulation burst may include a pulse train of pulses having 
amplitude with a minimum value of 0 Volts, a maximum 
value of 0.2 volts, a frequency of approximately 15,000 Hz 
and a duty cycle of approximately 37.5%. Further, the 
stimulation signal burst maybe amplitude modulated to form 
rectangular waveshapes, with the waveshapes having fre 
quencies Sweeping from 7 Hz to 12 HZ over approximately 
equal periods of time during the burst. 
0060. Further still to the method, the applying step may 
include the step of placing conductors to create a current 
pathway through at least one portion of the patient’s brain. 
Such portions of a brain may be selected from a group 
consisting of, but not limited to, the parietal lobes, Soma 
tosensory cortex, thalamus, prefrontal cortex, primary motor 
cortex, secondary motor cortex, insula or default mode 
network. In one embodiment, the conductors may be placed 
proximate to the portion of the brain to be stimulated. In 
another embodiment, a first conductor may be placed proxi 
mate to the parietal lobes along the median plane, and a 
second conductor may be placed proximate to the right ear. 
In another embodiment, a first conductor may be placed 
proximate to International 10-20 site PZ, and a second 
conductor may be placed proximate to the right ear lobe. In 
another embodiment, the conductors may be noninvasive. 
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0061 The method may be further realized by performing 
the applying and sequencing steps repeatedly over a period 
of time. In one embodiment, the applying and sequencing 
steps may be performed at least once a day, with at least one 
day transpiring between applications. In another embodi 
ment, the applying and sequencing steps may be performed 
twice in a calendar week, with two days transpiring between 
applications. In another embodiment, the applying and 
sequencing steps may be performed repeatedly over a period 
ranging from 8 to 24 consecutive weeks. In another embodi 
ment, the applying and sequencing steps may be performed 
repeatedly over a period of 12 consecutive weeks. In another 
embodiment, the applying and sequencing steps may be 
performed 24 times over the period of time. In another 
embodiment, the applying and sequencing steps may be 
performed additional times to further treat the neurological 
condition and achieve more satisfactory alleviation of symp 
tOmS. 
0062. A method is taught for treating a neurological 
condition in a patient. Such neurological conditions may 
include, but are not limited to, fibromyalgia, hyperalgesia, 
central pain, central sensitivity, chronic pain, abnormal brain 
network connectivity, neuropathic pain, central pain arising 
from chronic osteoarthritis, central pain arising from chronic 
back pain, chronic headache, migraine headache or depres 
Sion. The method may include placing a first conductor on 
the patient’s head proximate to International 10-20 site PZ 
and placing a second conductor proximate to the patients 
right ear lobe; then applying an electrical stimulation signal 
between the first and second conductors, where the electrical 
stimulation signal may include a tissue transmission com 
ponent which may further include a monopolar pulse train of 
frequency sufficient to reduce tissue impedance between the 
conductors and the patient's brain, and where the pulse train 
amplitude may have a minimum value of 0 Volts, a maxi 
mum value of 0.2 volts, a frequency of approximately 
15,000 Hz and a duty cycle of approximately 37.5%, and 
where the pulse train may be amplitude modulated to form 
a rectangular waveshape with frequencies ranging from 7 HZ 
to 12 HZ, as a function of time; then sequencing the appli 
cation of the electrical stimulation signal in a burst and rest 
time sequence consisting of a first three minute period of 
rest; and then after the first period of rest, applying a first 
burst of the electrical stimulation signal for 30 seconds, with 
frequencies sweeping from 7 Hz to 12 Hz over approxi 
mately equal periods of time during the burst; and then after 
applying the first burst, ceasing application of the electrical 
stimulation signal for a second period of rest lasting 60 
seconds; and then after the second period of rest, applying 
a second burst of the electrical stimulation signal for 60 
seconds, with frequencies sweeping from 7 Hz to 12 Hz over 
approximately equal periods of time during the burst; and 
then after applying the second burst, ceasing application of 
the electrical stimulation signal for a third period of rest 
lasting 60 seconds; and then after the third period of rest, 
applying a third burst of the electrical stimulation signal for 
90 seconds, with frequencies sweeping from 7 Hz to 12 HZ 
over approximately equal periods of time during the burst; 
and then after applying the third burst, ceasing application of 
the electrical stimulation signal for a fourth period of rest 
lasting three minutes; and then performing the placing, 
applying and sequencing steps twice in a calendar week, 
with at least one day transpiring between treatment appli 
cations, over a period of 12 consecutive weeks. 
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0063 A method is taught for treating a neurological 
condition in a patient. Such neurological conditions may 
include, but are not limited to, fibromyalgia, central sensi 
tivity, central pain, abnormal neural network connectivity, 
complex regional pain syndrome, phantom pain, irritable 
bowel syndrome, temporomandibular disorder, myofascial 
pain syndrome, regional Soft-tissue pain syndrome, neuro 
pathic pain, osteoarthritis, back pain, post-operative pain, 
depression, tension-type headaches or migraine headaches. 
0064. The method may include the step of applying an 
electrical stimulation from conductors to the patient’s head 
at a stimulation application site, and in which the electrical 
stimulation may include a composite electrical signal which 
may further include at least one signal form configured to 
provide long-term treatment of the neurological condition 
and at least one signal form configured to provide analgesia 
for short-term pain relief. 
0065. In one embodiment, the at least one signal form 
configured to provide long-term treatment of the neurologi 
cal condition and the at least one signal form configured to 
provide analgesia for short-term pain relief may be applied 
simultaneously during a treatment application. In another 
embodiment, the at least one signal form configured to 
provide long-term treatment of the neurological condition 
and the at least one signal form configured to provide 
analgesia for short-term pain relief may be applied at 
alternating times during a treatment application. 
0066. In one embodiment, the at least one signal form 
configured to provide long-term treatment of the neurologi 
cal condition may include an electrical signal configured to 
treat an abnormal brain condition associated with the neu 
rological condition. In another embodiment, the at least one 
signal form configured to provide analgesia for short-term 
pain relief may include an electrical signal configured to 
stimulate modulation of one or more neurotransmitters asso 
ciated with analgesia. Further to the embodiment, the modu 
lation may be selected from a group consisting of, but not 
limited to, the release, expression, uptake, increased pro 
duction, reduced production, inhibition or elimination of 
neurotransmitters. Further to the embodiment, the neu 
rotransmitters may be selected from a group consisting of 
but not limited to, serotonin, norepinephrine, glutamate, 
N-Methyl-D-aspartic acid, Substance P, gama-aminobutyric 
acid, various nucleotides or dopamine. 
0067. In an embodiment of the method, the at least one 
signal form configured to provide long-term treatment of the 
neurological condition may include a tissue transmission 
component and a therapeutic component. Further to the 
embodiment, the tissue transmission component may 
include a pulse train of frequency Sufficient to reduce tissue 
impedance between the conductors and the patient’s brain. 
Further still, the pulse train amplitude may have a minimum 
value of 0 volts and a maximum value of 1 volt. In another 
embodiment, the pulse train amplitude may have a maxi 
mum value of 0.2 volts. In one embodiment, the pulse train 
frequency may be between 10,000 Hz and 20,000 Hz. In 
another embodiment, the pulse train frequency may be 
approximately 15,000 Hz. In the embodiments, the pulse 
train may be monopolar. Further to the embodiments, the 
electrical stimulation may be subthreshold for detection by 
the patient. 
0068. Further to the method, the pulse train may be pulse 
width modulated to create a variable duty cycle of on time 
and off time. In one embodiment, the pulse train duty cycle 
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may be between 20% and 60%. In another embodiment, the 
pulse train duty cycle may be approximately 37.5%. Further 
still to the method, the pulse train may be amplitude modu 
lated to create a waveshape which may include an amplitude 
envelope. In one embodiment, the waveshape may form a 
therapeutic component. In another embodiment, the ampli 
tude envelope may form a rectangular wave. In another 
embodiment, the amplitude envelope may form a sinusoidal 
wave. In another embodiment, the amplitude envelope may 
form a composite of multiple sinusoidal waves. In one 
embodiment, the waveshape may have a frequency between 
1 Hz and 30 Hz. In another embodiment, the waveshape may 
have a frequency between 7 Hz and 12 Hz. In another 
embodiment, the waveshape is a rectangular wave with 
frequencies ranging from 7 Hz to 12 HZ, as a function of 
time. In another embodiment, multiple sinusoidal waves 
may have individual frequencies between 1 Hz, and 30 Hz. 
Further to the method, the frequency of the waveshape may 
change as a function of Stimulation delivery time. 
0069. In one embodiment of the method, a pulse train 
may have amplitude with minimum value of 0 volts and 
maximum value of 0.2 volts, a frequency of approximately 
15,000 Hz, and a duty cycle of approximately 37.5%. 
0070 Further to the method, stimulation may be applied 
in bursts with periods of time ranging from 1 second to 5 
minutes. In one embodiment, each burst period may range in 
time from 30 seconds to 2 minutes. Further still, each rest 
period may range in time from 1 second to 5 minutes. In one 
embodiment, each rest period may be 60 seconds. 
0071. Further still, the electrical stimulation may include 
a sequencing step in which an electrical signal is applied in 
bursts for at least two burst periods with at least one rest 
period which may include no stimulation in between each 
pair of bursts. In one embodiment, each burst period may 
range in time from 1 second to 5 minutes. In another 
embodiment, each burst period may range in time from 30 
seconds to 2 minutes. In one embodiment, each rest period 
may range in time from 1 second to 5 minutes. In another 
embodiment, each rest period may be 60 seconds. 
0072 Further still to the method, the patient’s electroen 
cephalogram (EEG) signal may be measured, including 
times when EEG may be measured during a rest period. In 
one embodiment, the EEG may be measured at the stimu 
lation application site. In another embodiment, the patients 
EEG signal may be measured during a period of rest prior to 
a first burst of stimulation signal. In an embodiment, Such 
periods of rest prior to a first burst may range in time from 
1 second to 5 minutes. In another embodiment, such period 
of rest prior to a first burst may be 3 minutes. 
0073. Further still to the method, the patient's EEG signal 
may be measured during a period of rest after a final burst 
of stimulation signal. In an embodiment, such periods of rest 
after a final burst may range in time from 1 second to 5 
minutes. In another embodiment, such period of rest after a 
final burst may be 3 minutes. 
0074. Further still to the method, the sequencing step 
may include a burst and rest time sequence consisting of a 
first three minute period of rest; then applying a first burst of 
the electrical stimulation signal for 30 seconds; then after 
applying the first burst, ceasing application of the electrical 
stimulation signal for a second period of rest lasting 60 
seconds; then after the second period of rest, applying a 
second burst of the electrical stimulation signal for 60 
seconds; then after applying the second burst, ceasing appli 
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cation of the electrical stimulation signal for a third period 
of rest lasting 60 seconds; then after the third period of rest, 
applying a third burst of the electrical stimulation signal for 
90 seconds; and then after applying the third burst, ceasing 
application of the electrical stimulation signal for a fourth 
period of rest lasting three minutes. In the embodiments, the 
stimulation burst may include a pulse train of pulses having 
amplitude with a minimum value of 0 Volts, a maximum 
value of 0.2 volts, a frequency of approximately 15,000 Hz 
and a duty cycle of approximately 37.5%. Further, the 
stimulation signal burst maybe amplitude modulated to form 
rectangular waveshapes, with the waveshapes having fre 
quencies Sweeping from 7 Hz to 12 HZ over approximately 
equal periods of time during the burst. 
0075. Further to the method, the at least one signal form 
configured to provide analgesia for short-term pain relief 
may include a periodic signal. In one embodiment, the 
periodic signal may be a pulse train. In another embodiment, 
the periodic signal may be a sinusoidal waveform. In another 
embodiment, the periodic signal may have frequencies 
between 1 Hz and 300 Hz. In another embodiment, the 
periodic signal may have frequencies between 50 Hz, and 
150 Hz. In another embodiment, the periodic signal may 
have a frequency of approximately 60 Hz. In another 
embodiment, the periodic signal may have a frequency of 
approximately 120 Hz. In one embodiment, the periodic 
signal may have amplitudes between -10 volts and +10 
Volts. In another embodiment, the periodic signal may have 
a minimum amplitude of -1 volts and maximum amplitude 
of +1 volt. 
0076 Further to the method, the at least one signal form 
configured to provide analgesia for short-term pain relief 
may be applied during periods of rest time before or after 
bursts of at least one signal form configured to provide 
long-term treatment of a neurological condition. Further 
still, the at least one signal form configured to provide 
analgesia for short-term pain relief may include a direct 
current (DC) signal. 
0077. Further still to the method, the applying step may 
include the step of placing conductors to create a current 
pathway through at least one portion of the patient’s brain. 
Such portions of a brain may be selected from a group 
consisting of, but not limited to, the parietal lobes, Soma 
tosensory cortex, thalamus, prefrontal cortex, primary motor 
cortex, secondary motor cortex, insula or default mode 
network. In one embodiment, the conductors may be placed 
proximate to the portion of the brain to be stimulated. In 
another embodiment, a first conductor may be placed proxi 
mate to the parietal lobes along the median plane, and a 
second conductor may be placed proximate to the right ear. 
In another embodiment, a first conductor may be placed 
proximate to International 10-20 site PZ, and a second 
conductor may be placed proximate to the right ear lobe. In 
another embodiment, the conductors may be noninvasive. 
0078. The method may be further realized by performing 
the applying and sequencing steps repeatedly over a period 
of time. In one embodiment, the applying and sequencing 
steps may be performed at least once a day, with at least one 
day transpiring between applications. In another embodi 
ment, the applying and sequencing steps may be performed 
twice in a calendar week, with two days transpiring between 
applications. In another embodiment, the applying and 
sequencing steps may be performed repeatedly over a period 
ranging from 8 to 24 consecutive weeks. In another embodi 
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ment, the applying and sequencing steps may be performed 
repeatedly over a period of 12 consecutive weeks. In another 
embodiment, the applying and sequencing steps may be 
performed 24 times over the period of time. In another 
embodiment, the applying and sequencing steps may be 
performed additional times to further treat the neurological 
condition and achieve more satisfactory alleviation of symp 
tOmS. 
007.9 Further to the method, the applying step may 
include applying electrical stimulation through conductors 
that create at least a first current pathway through at least a 
first portion of the patient’s brain for providing long-term 
treatment of the neurological condition, and at least a second 
current pathway through at least a second portion of the 
patient’s brain for providing analgesia for short-term pain 
relief. In one embodiment, the conductors may include at 
least two electrical leads placed proximate to the portion of 
the patient’s brain to be stimulated. In another embodiment, 
the conductors may be noninvasive. 
0080 A method is taught for treating a neurological 
condition in a patient. Such neurological conditions may 
include, but are not limited to, fibromyalgia, hyperalgesia, 
central pain, central sensitivity, chronic pain, abnormal brain 
network connectivity, neuropathic pain, central pain arising 
from chronic osteoarthritis, central pain arising from chronic 
back pain, chronic headache, migraine headache or depres 
Sion. The method may include placing a first electrical lead 
on the patients head proximate to International 10-20 site 
PZ and placing a second electrical lead proximate to the 
patient’s right ear lobe; and then applying a composite 
electrical stimulation signal which may include a signal 
configured to provide long-term treatment of the neurologi 
cal condition and a signal configured to provide analgesia 
for short-term pain relief, where the signal configured to 
provide analgesia for short-term pain relief may include a 
pulse train of both 60 Hz positive pulses and 60 Hz, negative 
pulses, where the positive pulses may have a minimum 
amplitude of 0 volts and a maximum amplitude of 0.5 volts, 
where the negative pulses may have a maximum amplitude 
of 0 volts and a minimum amplitude of -0.5 volts, where the 
positive and negative pulses may alternate in time and may 
be equally spaced in time, where the signal to provide 
long-term treatment of the neurological condition may 
include a monopolar pulse train of frequency Sufficient to 
reduce tissue impedance, where the pulse train amplitude 
may have a minimum value of 0 Volts, a maximum value of 
0.2 volts, a frequency of approximately 15,000 Hz and a 
duty cycle of approximately 37.5%, and where the pulse 
train may be amplitude modulated to form a rectangular 
waveshape with frequencies which ranging from 7 Hz to 12 
HZ as a function of time; and then sequencing application of 
the electrical stimulation signal in a burst and rest time 
sequence that may consist of a first burst which may include 
the signal configured to provide analgesia for short-term 
pain relief, lasting three minutes, then a second burst which 
may include the signal configured to provide long-term 
treatment of the neurological condition, lasting 30 seconds, 
with frequencies sweeping from 7 Hz to 12 Hz over approxi 
mately equal periods of time during the burst, and then a 
third burst which may include the signal configured to 
provide analgesia for short-term pain relief, lasting 60 
seconds, and then a fourth burst which may include the 
signal configured to provide long-term treatment of the 
neurological condition, lasting 60 seconds, with frequencies 
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sweeping from 7 Hz to 12 Hz over approximately equal 
periods of time during the burst, and then a fifth burst which 
may include the signal configured to provide analgesia for 
short-term pain relief, lasting 60 seconds, and then a sixth 
burst which may include the signal configured to provide 
long-term treatment of the neurological condition, lasting 90 
seconds, with frequencies sweeping from 7 Hz to 12 Hz over 
approximately equal periods of time during the burst; and 
then a seventh burst which may include the signal config 
ured to provide analgesia for short-term pain relief, lasting 
three minutes; and then conducting the electrical stimulation 
along a current pathway which may be created between the 
first electrical lead placed proximate to International 10-20 
site PZ, and the second electrical lead placed proximate to 
the right earlobe; and then performing the placing, applying 
and sequencing steps twice in a calendar week, with at least 
one day transpiring between treatment applications, over a 
period of 12 consecutive weeks. 
I0081. An electrical stimulation apparatus is taught which 
may include an electrical signal generator adapted to provide 
an electrical signal form configured to provide long-term 
treatment of a neurological condition and to provide an 
electrical signal form configured to provide analgesia for 
short-term pain relief. In one embodiment, the electrical 
signal generator may further include at least one microcon 
troller configured to generate composite signal waveforms 
and coupled to at least one signal conditioning circuit 
configured to transform the composite signal waveforms 
into stimulation signals. Further to the embodiment, the at 
least one signal conditioning circuit may include an ampli 
fier circuit. 
0082 In another embodiment, the electrical stimulation 
apparatus may further include any one or more circuit 
elements selected from the group of circuit elements con 
sisting of, but not limited to, an EEG amplifier configured to 
measure EEG signals, a filter circuit configured to reduce 
electrical noise in EEG signals, an isolation amplifier con 
figured to protect human Subjects, an analog-to-digital inter 
face configured to convert analog EEG signals to digital 
signals, and an isolated power Supply configured to provide 
circuit power and human Subject protection. 
I0083. Further still, an embodiment of the apparatus may 
further include at least two electrical leads for providing a 
composite stimulation signal current pathway between the 
electrical signal generator and a tissue to be stimulated. In 
another embodiment, the apparatus may further include a 
user interface, which may further include a software graphic 
user interface which provides user guidance for providing a 
composite stimulation signal. 
BRIEF DESCRIPTION OF THE DRAWINGS 
0084. The novel features of the invention are set forth 
with particularity in the claims that follow. A better under 
standing of the features and advantages of the present 
invention will be obtained by reference to the following 
detailed description that sets forth illustrative embodiments, 
in which the principles of the invention are utilized, and the 
accompanying drawings of which: 
I0085 FIG. 1 shows an apparatus for providing electrical 
stimulation according to an embodiment of the invention. 
I0086 FIG. 2 shows an example composite stimulation 
signal featuring one signal form configured for providing 
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long-term treatment of a neurological condition and a sec 
ond signal form configured for providing analgesia for 
short-term pain relief. 
0087 FIG. 3 shows a block diagram of a composite 
electrical signal generator apparatus according to an 
embodiment of the invention. 
0088 FIG. 4 shows a block diagram of a composite 
electrical signal generator apparatus to manage timing of the 
therapy application according to an embodiment of the 
invention. 
DETAILED DESCRIPTION 
0089. While the use of electrical stimulation for thera 
peutic purposes has been taught through numerous examples 
in the art, the methods and apparatuses described herein 
provide several advantages and improvements over previ 
ously disclosed matter. 
0090 Disclosed herein is an electrical stimulation system 
involving forms of electrical stimulation signals and treat 
ment delivery strategies that have been shown in clinical 
research trials to provide therapeutic advantages and lasting 
results in persons suffering from fibromyalgia and similar 
pain conditions involving central pain. 
0091. A key element of the electrical stimulation methods 
taught herein is the utilization of stimulation signal forms 
that include (1) a transmission component configured to 
enhance the ability of the signal to transmit through tissues 
to be stimulated, and to do so in a way that reduces 
attenuation due to tissue impedance; and (2) a therapeutic 
component configured to treat mechanisms involved in 
central pain, such as central sensitivity and abnormal neural 
network connectivity in the brain. In this invention, the 
therapeutic signal component may be configured to treat 
nociceptive pain or provide analgesia. Alternately, the thera 
peutic signal component may be configured to reduce aber 
rant brain function mechanisms such as those that process 
pain signals in ways that cause abnormal perception of pain. 
In other words, the methods taught herein target abnormal 
pain processing mechanisms, but may also treat nociceptive 
generators of pain or block pain signals ascending from 
peripheral nerves. 
0092 Such signal components configured to enhance 
signal transmission include the use of a pulse train of 
frequency high enough to reduce the electrical admittivity of 
intervening tissues between a conductor and the brain. In 
one embodiment, the pulse train is monopolar so as to 
deliver a positive net charge to the patient. It may also be 
pulse width modulated in a way that advantageously creates 
a variable duty cycle. This is done to provide control of the 
time averaged power delivered by the pulse train signal. 
0093. The method is further realized when the pulse train 
is amplitude modulated to create a waveshape comprising an 
amplitude envelope approximately following the peak val 
ues of the amplitude modulated pulses. The waveshape is 
created in a way that the amplitude envelope forms another 
periodic signal having at least one frequency lower than the 
frequency of the pulse train. Such periodic signals may be 
realized through any waveform, Such as a rectangular wave, 
a sinusoidal wave, or a composite of multiple sinusoidal 
waves. The frequencies of the waveshape may be fixed, or 
they may change over time as the stimulation signal is being 
delivered. Advantages of changing frequencies over time 
may include the ability to provide (1) a broader range of 
frequency-dependent stimulation benefits in a single therapy 
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application, and (2) a sequential adjustment of stimulation 
frequency that may prevent overstimulation of the brain at 
any particular frequency. 
0094. The lower frequency waveshape provides the 
stimulation signals therapeutic component configured to 
treat mechanisms involved in central pain, such as central 
sensitivity and abnormal neural network connectivity in the 
brain. In combination, the signal component configured to 
enhance signal transmission and the therapeutic lower fre 
quency waveshape provides a stimulation signal that can be 
effectively transmitted through tissues with lower driving 
Voltages. The advantages of this include greater safety in the 
stimulation signal, and the ability to provide therapeutic 
electrical stimulation with signals that are subthreshold for 
detection by a patient being stimulated. In treating patients 
who are suffering from enhanced pain processing, and are 
therefore experiencing allodynia and/or hyperalgesia, the 
ability to stimulate without the signal itself causing pain or 
any negative sensation is a significant advantage. 
0.095 The signal method may further include a signal 
component that is configured to provide analgesia for short 
term pain relief. While a signal featuring components to 
reduce aberrant brain function mechanisms that process pain 
signals in ways that cause an abnormal perception of pain 
has long-term therapeutic utility, actual pain relief experi 
enced by the patient may not be immediate. Thus, in some 
embodiments the method uses additional signal components 
that may, among other things, modulate neurotransmitters in 
the body to cause analgesia and short-term pain relief. 
0096 Such signals configured to provide analgesia may 
include a DC signal or a periodic signal Such as pulse trains 
or sinusoidal waveforms. Such periodic signals may have 
frequencies between 1 Hz and 300 Hz, which is a range of 
frequencies sometimes known as the “physiologic stimula 
tion range'. Other frequencies may be selected to stimulate 
certain neurotransmitters. For example, it is known that 
frequencies in the range of 50-150 Hz, may stimulate the 
release of the pain mediating neurotransmitters dopamine, 
serotonin and norepinephrine. Such periodic signals may 
also have both positive and negative amplitudes ranges, such 
as for example between -1 volt and +1 volt. 
0097. The method is further realized when the electrical 
stimulation signals are delivered in a therapeutic setting, 
using repeat applications and over a period of time. The 
advantages of repeat applications over a period of time 
include the provision of therapy that modulates the abnormal 
pain processing mechanisms associated with fibromyalgia 
and other neurological conditions involving central pain, 
reinforces normal pain processing mechanisms, and there 
fore creates a lasting therapeutic benefit. 
0098. Further to the method, the repeat applications of 
therapy involve signal deliveries in bursts typically lasting 
anywhere from a few seconds to several minutes. Before, 
after and in between these bursts, the method involves 
periods of therapeutic rest in which the patient remains in a 
state for receiving stimulation, but no stimulation signal is 
actually delivered. Such state for receiving stimulation may 
include the patient being physically connected to conductors 
of an electrical stimulation apparatus, sitting still in a clinical 
environment during which time their eyes are closed and 
they are purposefully told to relax. 
0099. During such rest periods, the patient merely spends 
time in a state of relaxation and disengagement from general 
attentiveness to their Surroundings. Providing such rest 
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periods may be therapeutically advantageous in that the 
mechanisms associated with abnormal pain processing, for 
example hyperconnectivity in brain networks, may diminish 
or mitigate when a patient is in Such state. When the 
stimulation bursts are Subsequently applied, the stimulation 
may reinforce states Such as a reduced connective state, and 
therefore reinforce the therapeutic benefit. 
0100 Further still to the method, the therapy applications 
may be provided over a period of several days per week and 
several weeks per a course of therapy. The advantage of Such 
approach is again conceived to provide long-term therapeu 
tic benefit. The method also anticipates a therapeutic advan 
tage of providing at least one day in between therapy 
applications, during which time the patient will receive no 
stimulation therapy. 
0101. Further still to the method, the patient’s electroen 
cephalogram (EEG) signal may be measured at times con 
sistent with the therapy application. In one embodiment, 
EEG may be measured during periods of rest. In another 
embodiment, EEG may be measured at the electrical stimu 
lation signal application site. In yet another embodiment, 
EEG may be measured at a number of additional sites on the 
Scalp. The uses for EEG measurement at the signal appli 
cation site include means of assuring the integrity of elec 
trical contact between conductors and the patient, and thus 
assuring quality stimulation signal delivery. The uses for 
EEG measurement at additional sites on the scalp include 
providing a means for assessing brain neural network con 
nectivity before, during and after stimulation signal appli 
cation, the benefits of which may include providing indica 
tion of the levels and characteristics of at least one parameter 
of abnormal pain processing mechanisms in the brain. 
0102. With reference to FIG. 1, the method may be 
practiced by using an apparatus 1 configured to generate 
electrical stimulation signals, and in particular the kinds of 
composite electrical stimulation signals disclosed herein. In 
one embodiment. Such apparatus 1 includes conductors 2 
that are adapted to rest on the patient’s head 3. Therapy 
begins after a patient 4 presents in clinic and is taken to a 
clinical setting, which may include a quiet room in which 
lighting can be reduced, and in which the room contains a 
comfortable chair for the patient to use during therapy and 
which has adequate Support for the patient's head 3 and 
neck. The conductors 2 are used to establish electrical 
contact between the apparatus 1 and the patient’s head 3. 
Such contact may be enhanced by using cutaneous elec 
trodes 5 and electrically conductive gel, both of which are 
well known in the art of electrophysiological measurements. 
0103) The conductors 2 are placed in a way such that the 
stimulation signal will pass through or proximate brain 
tissues to be stimulated. In various embodiments, such brain 
tissues may include, but are not limited to, the parietal lobes, 
Somatosensory cortex, thalamus, prefrontal cortex, primary 
motor cortex, secondary motor cortex, insula or default 
mode network. 
0104. Once electrical contact is established, the rooms 
lighting is typically reduced and the patient 4 is encouraged 
to close their eyes and relax. At that point, a clinical 
professional causes the apparatus 1 to start the therapy 
application, which starts a timer internal to the apparatus 1. 
The therapy application, using burst and rest sequences as 
described herein, is then applied according to the timing of 
the apparatus 1. 
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0105. With specific reference to the embodiments, a 
method is provided for treating fibromyalgia, which is a 
chronic full body pain condition featuring centralized pain, 
and in many cases, underlying conditions that also cause 
nociceptive pain. A method is also provided for treating 
other central pain related neurological conditions, which 
include but are not limited to hyperalgesia, central pain, 
central sensitivity, chronic pain, abnormal brain network 
connectivity, neuropathic pain, central pain arising from 
chronic osteoarthritis, central pain arising from chronic back 
pain, chronic headache, migraine headache or depression. 
All of these conditions either feature or are believed to be 
causally related to centralized pain, which is further believed 
to be related to central sensitivity and abnormal neural 
network connectivity in pain processing areas of the brain. 
0106. The method includes the use of an electrical stimu 
lation signal configured to reduce tissue impedance and 
deliver stimulation to brain tissues without being perceived 
by a patient 4 who is receiving the stimulation. In a preferred 
embodiment, the electrical stimulation signal comprises a 
tissue transmission signal further comprising a pulse train of 
frequency Sufficient to reduce tissue impedance. Further, the 
individual pulses in the pulse train are pulse width modu 
lated to create a variable duty cycle of on time and off time. 
Such pulse width modulation is conceived to control the 
time-averaged power delivered over an individual period of 
the pulses in the pulse train. Further still, the electrical 
stimulation signal comprises a therapeutic signal created by 
amplitude modulating the pulse train of the tissue transmis 
sion signal to create a waveshape comprising an amplitude 
envelope. In some embodiments, the waveshape forms a 
stimulation signal of at least one lower frequency compared 
with the frequency of the pulse train, and it is this lower 
frequency signal that acts as the therapeutic signal. 
0107. In one embodiment, the pulse train amplitudes and 
frequencies are chosen to be subthreshold for detection by a 
person being stimulated. In some instances of prior art, 
electrical stimulation methods are taught that teach avoid 
ance of amplitudes and frequencies that are within the 
perceptible physiological stimulation range, that is, approxi 
mately between 1-300 Hertz (Hz), so as to prevent noxious 
sensations in a person receiving stimulation. However, the 
present invention teaches the combination of high frequency 
and low amplitude signals that are capable of providing 
stimulation within said physiological stimulation range that 
is not detected by a person receiving stimulation and still 
causes a therapeutic effect. 
0.108 Such combinations of signal amplitudes and fre 
quencies, in the embodiment, may include a pulse train with 
amplitude at a minimum value of 0 Volts and a maximum 
value of 1 volt. In the preferred embodiment, the pulse train 
amplitude has a maximum value of 0.2 volts. Such combi 
nations may also include a pulse train with frequencies 
between 10,000 Hz and 20,000 Hz. In the preferred embodi 
ment, the pulse train frequency is approximately 15,000 Hz. 
This range of frequencies has been shown in tissue modeling 
studies to effectively overcome the impedances of the tissues 
of the head 3, thus allowing a stimulation signal applied 
noninvasively to pass through outer tissues such as the scalp 
and skull with less attenuation. 
0109 Further to the embodiment, the pulse train may be 
of any form, Such as a monopolar waveform. Further still, 
the pulse train duty cycle may be between 20% and 60%. 
These duty cycles are anticipated to provide time-averaged 
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power levels that are effective. In one exemplary embodi 
ment, the pulse train duty cycle is approximately 37.5%. 
0110. Further still to the embodiments, the amplitude 
envelope formed by amplitude modulating the pulse train 
may form any waveshape. In one embodiment, the ampli 
tude envelope may form a rectangular wave. Such rectan 
gular waveshape may be advantageous as it has shown 
efficacy in clinical studies for treating pain in fibromyalgia. 
In another embodiment, the amplitude envelope forms a 
sinusoidal wave. In yet another embodiment, the amplitude 
envelope forms a composite of multiple sinusoidal waves. 
Such composite of multiple sinusoidal waves may be advan 
tageous in that multiple lower stimulating frequencies are 
represented by a single waveshape. 
0111. In all embodiments, the waveshape is configured as 
a periodic waveform of frequencies sufficient to cause 
therapeutic electrical stimulation. In one embodiment, the 
waveshape has a frequency between 1 Hz and 30 Hz. This 
frequency range may also be used in embodiments involving 
multiple sinusoidal waves. This frequency range matches a 
range of frequencies commonly found in EEG signals in the 
human brain. In one embodiment, the waveshape has a 
frequency between 7 Hz and 12 Hz. This range provides 
stimulation in a range of frequencies commonly found in 
EEG signals in the human brain and representative of 
normal, alert conditions. In all embodiments, the frequency 
of the waveshape may be configured to change as a function 
of stimulation delivery time. 
0112. In one embodiment, a specific electrical stimulation 
method for treating fibromyalgia or other central pain related 
neurological conditions uses a pulse train which has a 
minimum amplitude value of 0 Volts, a maximum value of 
0.2 volts, a frequency of approximately 15,000 Hz and a 
duty cycle of approximately 37.5%. In the embodiment, the 
waveshape is a rectangular wave with frequencies ranging 
from 7 Hz to 12 Hz, as a function of time. Further to the 
embodiment, the electrical stimulation signal is applied in 
sequences of bursts for at least two periods of time with at 
least one period of rest time comprising no stimulation in 
between each signal application. In one embodiment, EEG 
signal may be measured as part of the method. In one 
embodiment, EEG may be measured at the stimulation 
application site during the periods of rest. The measurement 
of EEG would be apparent to one ordinarily skilled in the art. 
Further to the embodiment, the bursts of stimulation signal 
may range in time from 1 second to 5 minutes. In another 
embodiment, the bursts of Stimulation signal range in time 
from 30 seconds to 2 minutes. Further still to the embodi 
ment, the periods of rest range in time from 1 second to 5 
minutes. In another embodiment, the periods of rest are 60 
seconds. Further still to the embodiment, EEG signal is 
measured for a period of time prior to a first burst of 
stimulation signal, with said period of time prior ranging 
from 1 second to 5 minutes. In a preferred embodiment, the 
period of time prior to a first burst is 3 minutes. Likewise, 
in still another embodiment, EEG signal is measured for a 
period of time after a final burst of stimulation signal, with 
said period of time prior ranging from 1 second to 5 minutes. 
In a preferred embodiment, the period of time after a final 
burst is 3 minutes. 
0113. In one embodiment, the electrical stimulation com 
prises a burst and rest time sequence consisting of a first 
three minute period of rest, a first burst of stimulation signal 
lasting 30 seconds, a second period of rest lasting 60 
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seconds, a second burst of stimulation signal lasting 60 
seconds, a third period of rest lasting 60 seconds, a third 
burst of stimulation lasting 90 seconds, and a fourth period 
of rest lasting three minutes. In an exemplary embodiment, 
the stimulation signal burst is a pulse train that is amplitude 
modulated to form rectangular waveshapes, with said wave 
shapes having frequencies Sweeping from 7 Hz to 12 HZ 
over approximately equal periods of time during the burst. 
0114. Further to all embodiments of the methods taught 
herein, the electrical stimulation signal is conducted along a 
current pathway extending through at least one portion of a 
brain. In one embodiment, such portions of a brain are 
selected from those portions that are involved in central 
pain. Such portions of a brain may include, but are not 
limited to, the parietal lobes, somatosensory cortex, thala 
mus, prefrontal cortex, primary motor cortex, secondary 
motor cortex, insula or default mode network. Further to the 
embodiment, the method is accomplished by using at least 
two electrical leads that are either invasive or noninvasive, 
and are placed proximate to the portion of a brain to be 
stimulated, such that a current pathway includes said portion 
of a brain. In one embodiment, Such current pathway is 
provided by placing a first electrical lead proximate to the 
parietal lobes along the median plane of a human head3, and 
a second electrical lead is placed proximate to the right ear 
of the head 3. In another embodiment, another current 
pathway is provided by placing a first electrical lead proxi 
mate to International 10-20 electrode placement site PZ on a 
head 3, and a second electrical lead is placed proximate to 
the right ear lobe of the head 3. The placement of electrical 
leads and accomplishment of electrical interface is readily 
known to those of ordinary skill in the art. 
0115 Further to the method, treating fibromyalgia or 
other central pain related neurological conditions consists of 
treatment applications of the electrical stimulation signal 
methods taught herein, wherein the treatment applications 
are applied repeatedly over a period of time to cause a 
lasting therapeutic effect. In one embodiment, treatment 
applications are applied at least once a day, with at least one 
day transpiring between treatment applications during which 
time no electrical stimulation is applied to the patient 4. In 
another embodiment, treatment applications are applied 
twice in a calendar week, with two days transpiring between 
treatment applications. Further to the embodiment, treat 
ment is applied over a range of 8 to 24 weeks. In one 
exemplary embodiment, treatment comprises 24 treatment 
applications applied over a period of 12 consecutive weeks. 
The method is further accomplished when additional treat 
ment applications are applied as necessary to further treat 
the fibromyalgia and achieve more satisfactory alleviation of 
symptoms. 
0116. In one embodiment, a method of treating fibro 
myalgia or other central pain related neurological conditions 
is accomplished using an electrical stimulation signal com 
prising a monopolar pulse train of frequency Sufficient to 
reduce tissue impedance; wherein the pulse train amplitude 
has a minimum value of 0 volts, a maximum value of 0.2 
volts, a frequency of approximately 15,000 Hz and a duty 
cycle of approximately 37.5%; wherein the pulse train is 
amplitude modulated to form a rectangular waveshape with 
frequencies ranging from 7 Hz to 12 HZ, as a function of 
time; wherein each application of the electrical stimulation 
comprises the burst and rest time sequence consisting of a 
first three minute period of rest, a first burst of stimulation 
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signal lasting 30 seconds with frequencies Sweeping from 7 
HZ to 12 HZ over approximately equal periods of time during 
the burst, a second period of rest lasting 60 seconds, a 
second burst of Stimulation signal lasting 60 seconds with 
frequencies sweeping from 7 Hz to 12 Hz over approxi 
mately equal periods of time during the burst, a third period 
of rest lasting 60 seconds, a third burst of stimulation lasting 
90 seconds with frequencies sweeping from 7 Hz to 12 HZ 
over approximately equal periods of time during the burst 
and a fourth period of rest lasting three minutes; wherein the 
electrical stimulation is conducted along a current pathway 
created between a first electrical lead placed proximate to 
International 10-20 site PZ, and a second electrical lead 
placed proximate to the right ear lobe; in which the treatment 
applications are applied twice in a calendar week, with two 
days transpiring between treatment applications; and in 
which the treatment applications are applied over a period of 
12 consecutive weeks. 
0117. Further to the present invention, and with reference 
to FIG. 2, a method of treating a neurological condition is 
accomplished by using an electrical stimulation that is a 
composite signal 6 made up of multiple electrical signals. 
Such composite signal 6 may feature an electrical signal that 
has at least one signal form 7 configured to provide long 
term treatment of the neurological condition by providing 
electrical stimulation that is therapeutic to physiological 
mechanisms involved in the neurological condition. An 
example of Such physiological mechanisms may include 
abnormal brain conditions, such as excessive or insufficient 
neural network connectivity, and excessive or insufficient 
activity in brain regions associated with the neurological 
condition. Such composite 6 may further feature an electri 
cal signal that has at least one signal form 8 configured to 
provide analgesia for short-term pain relief, whether the pain 
is associated with the neurological condition or not. 
0118. The advantage of such composite signals 6 is to 
provide multiple therapeutic benefits to a person receiving 
electrical stimulation. In particular, a person Suffering from 
a neurological condition may experience multiple symptoms 
including pain. For example, a person Suffering from fibro 
myalgia may experience pain, fatigue, stiffness, cognitive 
impairment, depression, anxiety, symptoms of irritable 
bowel syndrome and abnormal sensitivities. These symp 
toms may all be linked to central sensitivity, which may 
further be linked to an abnormal brain condition such as 
abnormal neural network connectivity, and may therefore be 
neurological in nature. A composite signal 6 as taught herein 
may include a signal form 7 configured to provide therapy 
to the brain mechanisms that are related to the neurological 
condition, and thus provide long-term benefit and symptom 
relief. The composite signal may also provide an additional 
signal form 8 configured to provide symptom relief that is 
relatively immediate in comparison. In the method, Such 
additional signal form may be configured to provide short 
term pain relief, regardless of whether the pain is nocicep 
tive or central in nature. An example of Such additional 
signal form may be one configured to modulate one or more 
neurotransmitters associated with pain or analgesia. 
0119 The practice of such composite electrical signals 
may be accomplished using any number of methods well 
known in the art, such as but not limited to the Superposition 
of at least two individual signals. Such methods are known 
to a person ordinarily skilled in the art of electrical signal 
generation. 
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0.120. In one embodiment of the method, the at least one 
signal form 7 configured to provide long-term treatment of 
the neurological condition and the at least one signal form 8 
configured to provide analgesia for short-term pain relief 
may be applied simultaneously during a treatment applica 
tion. In another embodiment, the signal forms may be 
applied at alternating times during a treatment application. 
I0121 Further to the embodiment, the at least one signal 
form 7 configured to provide long-term treatment of the 
neurological condition may comprise an electrical signal 
configured to treat an abnormal brain condition associated 
with the neurological condition, and the at least one signal 
form 8 configured to provide analgesia for short-term pain 
relief comprises an electrical signal configured to stimulate 
modulation of one or more neurotransmitters associated with 
analgesia. Such modulation may be selected from a group 
consisting of the release, expression, uptake, increased pro 
duction, reduced production, inhibition or elimination of 
neurotransmitters. Such neurotransmitters may be selected 
from a group consisting of but not limited to serotonin, 
norepinephrine, glutamate, N-Methyl-D-aspartic acid, Sub 
stance P, gama-aminobutyric acid, various nucleotides or 
dopamine. Such neurological conditions may consist of but 
are not limited to fibromyalgia, central sensitivity, central 
pain, abnormal neural network connectivity, complex 
regional pain syndrome, phantom pain, irritable bowel syn 
drome, temporomandibular disorder, myofascial pain Syn 
drome, regional Soft-tissue pain syndrome, neuropathic pain, 
osteoarthritis, back pain, post-operative pain, depression, 
tension-type headaches or migraine headaches. 
0.122 Further to the method, the at least one signal form 
7 configured to provide long-term treatment of the neuro 
logical condition may comprise an electrical stimulation 
signal as taught herein configured to reduce tissue imped 
ance and deliver Stimulation to brain tissues without being 
perceived by a patient 4 who is receiving the stimulation. 
Further to the method, EEG signal may also be measured as 
part of the method and as taught herein. In one embodiment, 
EEG may be measured at the stimulation application site. 
I0123. Further to the method, the at least one signal form 
8 configured to provide analgesia for short-term pain relief 
may comprise a periodic signal Such as, but not limited to, 
a pulse train or a sinusoidal waveform. In one embodiment, 
the periodic signal has frequencies between 1 Hz and 300 
HZ, which is consistent with the physiologic stimulation 
frequency range as taught in Some examples of the art. In 
another embodiment, the periodic signal has frequencies 
between 50 Hz, and 150 Hz. Such frequencies have been 
shown to have the ability to modulate pain-related neu 
rotransmitters. In exemplary embodiments, the periodic sig 
nal has a frequency of approximately 60 Hz or approxi 
mately 120 Hz. Such frequencies may relieve pain in 
fibromyalgia. 
0.124. Further to the embodiments, the periodic signal 
may have amplitudes between -10 volts and +10 volts. In an 
exemplary embodiment, the periodic signal has minimum 
amplitude of -1 volts and maximum amplitude of +1 Volt. 
Further still, the at least one signal form conceived to 
provide analgesia for short-term pain relief 8 comprises a 
direct current (DC) signal. 
0.125 Further to the embodiments, the at least one signal 
form 8 configured to provide analgesia for short-term pain 
relief may be applied during periods of rest time before or 
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after sequences of bursts of at least one signal form 7 
configured to provide long-term treatment of a neurological 
condition. 
0126 Further to the method, the composite electrical 
stimulation signal 6 is conducted along at least one current 
pathway through at least one portion of a brain. Such 
portions of a brain may be selected from a group consisting 
of but not limited to the parietal lobes, somatosensory 
cortex, thalamus, prefrontal cortex, primary motor cortex, 
secondary motor cortex, insula or default mode network. 
Such current pathways may be created by placing at least 
two electrical leads proximate to the portion of a brain to be 
stimulated, as is previously taught herein. The method may 
also be accomplished by applying a composite electrical 
stimulation signal 6 using means that create at least a first 
current pathway through at least a first portion of a brain for 
providing long-term treatment of the neurological condition, 
and at least a second current pathway through at least a 
second portion of a brain for providing analgesia for short 
term pain relief. 
0127. Further to the method, the treatment of a neuro 
logical condition may be accomplished by providing treat 
ment applications of a composite electrical stimulation sig 
nal 6 applied repeatedly over a period of time to cause a 
lasting therapeutic effect. In one embodiment, treatment 
applications are applied at least once a day, with at least one 
day transpiring between treatment applications during which 
time no electrical stimulation is applied to the patient 4. In 
another embodiment, treatment applications are applied 
twice in a calendar week, with two days transpiring between 
treatment applications. Further to the embodiment, treat 
ment is applied over a range of 8 to 24 weeks. In a preferred 
embodiment, treatment comprises 24 treatment applications 
applied over a period of 12 consecutive weeks. The method 
is further accomplished when additional treatment applica 
tions are applied as necessary to further treat the fibromyal 
gia and achieve more satisfactory alleviation of symptoms. 
0128. In a preferred embodiment, a method of treating a 
neurological condition is accomplished using a composite 
electrical stimulation signal 6 which comprises a signal 7 
configured to provide long-term treatment of the neurologi 
cal condition, and which further comprises a signal 8 con 
figured to provide analgesia for short-term pain relief 
wherein the signal 8 configured to provide analgesia for 
short-term pain relief comprises a train of both 60 Hz 
positive pulses and 60 Hz negative pulses, in which the 
positive pulses have a minimum amplitude of 0 Volts and a 
maximum amplitude of 0.5 volts and the negative pulses 
have a maximum amplitude of 0 Volts and a minimum 
amplitude of -0.5 volts, and in which the positive and 
negative pulses alternate and are equally spaced in time; 
wherein the signal 7 configured to provide long-term treat 
ment of the neurological condition comprises a monopolar 
pulse train of frequency sufficient to reduce tissue imped 
ance, in which the pulse train amplitude has a minimum 
value of 0 volts, a maximum value of 0.2 volts, a frequency 
of approximately 15,000 Hz and a duty cycle of approxi 
mately 37.5% and is amplitude modulated to form a rect 
angular waveshape with frequencies ranging from 7 Hz to 
12 Hz as a function of time; wherein each application of the 
electrical stimulation comprises the burst sequence consist 
ing of a first burst lasting three minutes and comprising the 
signal 8 configured to provide analgesia for short-term pain 
relief, a second burst lasting 30 seconds and comprising the 
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signal 7 configured to provide long-term treatment of the 
neurological condition with frequencies Sweeping from 7 HZ 
to 12 HZ over approximately equal periods of time during 
the burst, a third burst lasting 60 seconds and comprising the 
signal 8 configured to provide analgesia for short-term pain 
relief, a fourth burst lasting 60 seconds and comprising the 
signal 7 configured to provide long-term treatment of the 
neurological condition with frequencies Sweeping from 7 HZ 
to 12 HZ over approximately equal periods of time during 
the burst, a fifth burst lasting 60 seconds and comprising the 
signal 8 configured to provide analgesia for short-term pain 
relief, a sixth burst lasting 90 seconds and comprising the 
signal 7 configured to provide long-term treatment of the 
neurological condition with frequencies Sweeping from 7 HZ 
to 12 HZ over approximately equal periods of time during 
the burst, and a seventh burst lasting three minutes and 
comprising the signal 8 configured to provide analgesia for 
short-term pain relief; wherein the electrical stimulation is 
conducted along a current pathway created between a first 
electrical lead placed proximate to International 10-20 site 
PZ, and a second electrical lead placed proximate to the right 
ear lobe; in which the treatment applications are applied 
twice in a calendar week, with two days transpiring between 
treatment applications; and in which the treatment applica 
tions are applied over a period of 12 consecutive weeks. 
I0129. Further to the present invention, and with reference 
to FIG. 3, an electrical stimulation apparatus is provided 
comprising a composite electrical signal generator 9, with 
the composite electrical signal generator 9 further compris 
ing at least one apparatus 10 adapted to generate an electrical 
signal form configured to provide long-term treatment of a 
neurological condition and further comprising at least one 
apparatus 11 adapted to generate an electrical signal form 
configured to provide analgesia for short-term pain relief. 
0.130. In one embodiment, an apparatus 10 adapted to 
generate electrical stimulation signal forms configured to 
provide long-term treatment of a neurological condition is 
further configured to provide an electrical stimulation signal 
comprising a tissue transmission signal and a therapeutic 
signal. Further to the embodiment, an apparatus 11 adapted 
to generate electrical stimulation signal forms configured to 
provide analgesia for short-term pain relief further is further 
configured to provide an electrical stimulation signal con 
figured to modulate one or more neurotransmitters associ 
ated with analgesia. 
I0131 Numerous electrical circuit embodiments may be 
used to accomplish the apparatus. In one embodiment illus 
trated in FIG. 4, the composite electrical signal generator 
apparatus 13 may comprise a computing device Such as a 
microcontroller 14 configured to manage timing of the 
therapy application and to control timed Switching between 
periods of application of an electrical signal form configured 
to provide long-term treatment of a neurological condition, 
an electrical signal form configured to provide analgesia for 
short-term pain relief, and application of no signal to accom 
plish periods of rest. 
0.132. The apparatus 13 may further comprise a first 
signal circuit 15 configured to generate an electrical signal 
form configured to provide long-term treatment of a neuro 
logical condition. The apparatus 13 may further comprise a 
second-signal circuit 16 configured to generate an electrical 
signal form configured to provide analgesia for short-term 
pain relief. 
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0133. The apparatus 13 may further comprise a multi 
plexer circuit 17, which may be controlled by the micro 
controller 14 to selectively transmit output from either the 
first-signal circuit 15 or the second-signal circuit 16 onto a 
signal transmission conductor 18, or to transmit no signal to 
the signal transmission conductor 18 for accomplishing 
periods of rest. The apparatus 13 may further comprise a 
mixer circuit 19, which may be controlled by the microcon 
troller 14 to simultaneously transmit output from both the 
first-signal circuit 15 and the second-signal circuit 16 onto a 
signal transmission conductor 18, or to transmit no signal to 
the signal transmission conductor 18 for accomplishing 
periods of rest. 
0134. The embodiments might further comprise at least 
one signal conditioning circuit 20 configured to transform 
the generated signal waveforms into stimulation signals with 
desired Voltage, amperage and power characteristics. Such 
signal conditioning circuit 20 may comprise an amplifier 
circuit. In the embodiments, the apparatus may further 
comprise any one or more circuit elements selected from but 
not limited to the group of circuit elements consisting of an 
EEG amplifier configured to measure EEG signals, a filter 
circuit configured to reduce electrical noise in EEG signals, 
an isolation amplifier configured to protect human Subjects, 
an analog-to-digital interface configured to convert analog 
EEG signals to digital signals, and an isolated power Supply 
configured to provide circuit power and human Subject 
protection. 
0135 The embodiments may further comprise one or 
more conductors 2 electrically coupled to the signal trans 
mission conductor 18 and configured to deliver the com 
posite electrical signal from the composite electrical signal 
generator apparatus to a subject 4 being stimulated. 
0136. The embodiments may further comprise at least 
one safety circuit 21. In one such embodiment, a safety 
circuit 21 comprises a redundant timer circuit used to assure 
that an expected amount of stimulation time is not exceeded. 
Such safety circuit 21 may be used in case of a microcon 
troller 14 failure while the stimulation signal is being 
transmitted to the signal transmission conductor 18. Such 
safety circuit 21 might be configured to open the signal 
transmission conductor 18 if an expected maximum stimu 
lation time is exceeded, thus preventing the Subject 4 from 
receiving more stimulation than desired. 
0.137 The embodiments may further comprise a user 
interface 12, Such as but not limited to a software graphic 
user interface which provides user guidance for providing a 
composite stimulation signal. 
0.138. The invention is not limited in any way to the 
embodiments disclosed herein. In this regard, no attempt is 
made to show structural details of the disclosed apparatuses 
or process details of the disclosed methods in more detail 
than is necessary for a fundamental understanding of the 
disclosed apparatuses and methods. The description is 
intended only to make apparent to those skilled in the art 
how the several forms of the invention may be embodied in 
practice. 
Example 1 
0.139. A clinical trial entitled “The Clinical Effect of 
Low-Intensity Electromagnetic Field Neurostimulation in 
Fibromyalgia Syndrome Patients' (Hargrove et al. Pain 
Med. 2012 Jan: 13(1): 115-24. ClinicalTrials.gov registration 
NCT01180244) was conducted at two independent sites. It 
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utilized a randomized, double-blind sham controlled design 
with a subsequent unblinded crossover of sham treated 
patients. 
0140. The study was conducted on patients diagnosed 
with fibromyalgia using the American College of Rheuma 
tology's 1990 (ACR 1990) classification criteria. Patients 
received either active treatment using a signal form taught 
herein, or a sham treatment. Treatment was applied twice a 
week for a period of eleven consecutive weeks. Total stimu 
lation exposure at each treatment application was 3.0 min 
utes, for a total exposure time over the course of therapy of 
66 minutes. A uniform protocol including signal form, 
exposure time and exposure location was applied during 
each study visit, as described below. Since the signal forms 
taught herein are not perceived by patients, the sham con 
dition was created by simply not turning on the signal. 
(0.141. The specific protocol for the NCT01180244 study 
was as follows: 
0142. A total of 86 patients were enrolled in the study. Of 
these, no patients in the active treatment group Voluntarily 
discontinued therapy. Seven patients in the sham group 
discontinued therapy citing no therapeutic benefit as the 
reason. One patient in the intervention group failed to return 
for end of therapy assessment and examination (i.e. was lost 
to follow-up), therefore no end of therapy data was gathered. 
0.143 Eligibility of volunteers was assessed at screening 
that included a medical and Surgical history, a physical 
examination, completion of patient self-report question 
naires designed to provide some of the study’s outcome 
measures, an EEG test and a dolorimeter assessment of 
tender points (TePs) at 18 sites per the ACR 1990 classifi 
cation criteria. Key Subject inclusion criteria included hav 
ing a confirmed diagnosis of primary fibromyalgia per the 
ACR 1990 classification criteria and ongoing symptoms 
lasting at least 48 months with no recent remission or 
significant change. Patients with other pain related diagno 
ses, chronic neurological disorder or significant systemic 
disorders were excluded from enrollment. Subjects with 
psychiatric disorders, other than depression and anxiety, 
requiring separate treatment were also excluded from enroll 
ment. 
0144. Outcome measures included the Fibromyalgia 
Impact Questionnaire (FIO), the number of positive tender 
points (TePs) (i.e. those tender points eliciting a painful 
response with less than 4 kg/cm2 dolorimeter pressure), and 
the tender point pressure pain threshold (PPT) derived by 
summing the dolorimetry pain thresholds for each of the 18 
TePs assessed. In addition, all patients completed neurop 
sychiatric assessments, health outcomes questionnaires and 
a seven-question Sleep Visual Analog Scale (Sleep VAS) 
questionnaire. 
0145 Safety was evaluated by monitoring for patient 
reported adverse events (AES) during the study and at 
post-therapy examination. In addition, a Subset of patients 
participating in long-term follow-up was asked to disclose 
any significant changes in health. No treatment emergent 
serious adverse effects were encountered over the course of 
the study. No adverse events or negative effects of treatment 
were discovered in long-term follow-up. Patient-reported 
AEs during the course of therapy were minor and resolved 
without medical intervention. 
0146 Efficacy was evaluated following repeat screening 
procedures on each patient conducted 1-2 weeks after the 
completion of therapy. These procedures included a physical 
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examination, TeP and PPT evaluation, and repeat comple 
tion of outcome measures questionnaires. No assessment 
was done during the therapy period. 
0147 Table 1 provides a brief summary of outcomes data 
relevant to efficacy for the treatment of pain in fibromyalgia. 
Data provided is a measure of post-therapy to baseline 
differences presented as raw data, with percent change and 
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0148 Table 2 reports group comparison statistics for 30 
patients in the control (sham) group that underwent Subse 
quent unblinded crossover to actual intervention. The elec 
trical stimulation signal protocol used was the same as that 
used on the original active treatment group and taught 
herein. It should be noted that some of the patients in the 
control group chose not to participate in the unblinded 
p-values (statistical significance) in parentheses. 
TABLE 1. 
COSSOW phase. 
Treatment outcomes related to pain in fibromyalgia 
Patient self-reported 
Intervention Sham 
Outcome Measure Group Group Conclusion 
Post-therapy change and percent -1.8 (27%, -0.4 (7%, 
improvement in pain VAS assessed p < 0.001) p = 0.20) 
by the FIQ, paired t-test individual 
averages (range 0-10) 
Post-therapy group difference in 
pain VAS assessed by the FIQ, t 
test on group averages 
Post-therapy change and percent 
improvement in overall FIQ score, 
paired t-test individual averages 
(range 0-100) 
Post-therapy group difference in 
overall FIQ score, t-test on group 
averages 
Post therapy change and percent 
improvement in number of positive 
(range 0-600) 
Post-therapy group difference in 
sleep VAS score, t-test on group 
averages 
1.3 (20%, p = 0.02) 
-13.6 (22%, 
p < 0.001) 
–4.3 (7%, 
p = 0.054) 
9.3 (15%, p = 0.01) 
–7.3 (42%, 
p < 0.001) 
-0.1 (1%, 
p = 0.67) 
75.8 (42%, p = 0.01) 
improvement in pain, as 
evidenced by changes in pain 
VAS, shows significant 
improvement in the intervention 
group, and no significant 
change in the sham group. 
Group outcome differences are 
significant. 
Patient self-reported 
improvement in fibromyalgia 
specific symptoms, as 
evidenced by changes in the 
overall FIQ score, shows 
significant improvement in the 
intervention group, and no 
significant change in the sham 
group. Group outcome 
differences are significant. 
The therapy resulted in 
significant improvement in the 
TePs, paired t-test individual number of tender points in the 
averages (range 0-18) intervention group, and no 
Post-therapy group difference in 6.9 (41%, p < 0.001) change in the sham group. 
number of positive TePs, t-test on Group outcome differences are 
group averages significant. 
Post therapy change and percent +19.1 (52%, -2.7 (-7%, The therapy resulted in 
improvement in PPT, paired t-test p < 0.001) p = 0.04) significant improvement in the 
individual averages (range 9-72) PPT in the intervention group. 
Post-therapy group difference in 21.8 (59%, p<0.001) The sham group showed a 
PPT, t-test on group averages significant worsening in PPT (p = 
0.04). Group outcome 
differences are significant. 
Post-therapy change and percent -105.8 -30.0 (11%, Patient self-reported 
improvement in sleep VAS score, (53%, p = 0.13) improvement in sleep, as 
paired t-test individual averages p < 0.001) evidenced by changes in the 
sleep VAS score, shows 
significant improvement in the 
intervention group, and no 
significant change in the sham 
group. Group outcome 
differences are significant. 
TABLE 2 
Group comparison of unblinded crossover patients 
N - 30 test on group averages 
Post-Sham 
Baseline to to 
Baseline Post-Sham Crossover Post-Sham Crossover 
Outcome Measure Mean SD Mean SD Mean SD p-value p-value 
FIQ Pain VAS score 6.1 2.4 5.9 (2.7 4.5 2.8) O.84 O.O6 
Overall FIQ score 55.6 (17.3 50.9 (20.2 37.6 (20.9) O.38 O.O3 
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TABLE 2-continued 
Group comparison of unblinded crossover patients 
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N = 30, t-test on group averages 
Post-Sham 
Baseline to to 
Baseline Post-Sham Crossover Post-Sham Crossover 
Outcome Measure Mean SD Mean SD Mean SD p-value p-value 
Number of positive TePs 16.8 1.9) 16.6 (1.9) 7.6 (4.6) 0.79 <0.001 
PPT, t-test on group 38.9 11.9) 35.99.5 61.0 (7.7 O.29 <0.001 
averages 
SD—standard deviation 
0149 Additional study data show that the electrical 
stimulation therapy also resulted in significant improve 
ments in other symptoms associated with fibromyalgia. 
There were no site, evaluator or treating clinician effects that 
altered the results. 
0150. A follow-up study was completed with a cohort of 
study participants (Hargrove et al. Arch Phys Med Rehabil. 
2012 October; 93(10): 1868-71). The follow up included a 
symptom Survey and the FIQ, and was intended to collect 
information concerning the long-term safety and efficacy of 
the electrical stimulation treatment taught herein. 
0151. Of the original 86 participants, 39 patients who 
were able to be contacted were mailed follow-up surveys. A 
study and 31.8 at follow-up. One-way repeat measures 
ANOVA using the Holm-Sidak correction for multiple com 
parisons showed both end of study and follow-up scores 
were significantly different from baseline (P<0.001). 
Although follow-up scores were numerically Superior to end 
of study scores, this difference was not significant (P=0.35). 
The FIQ score differences between baseline and end of 
study, and baseline and follow-up, were calculated for each 
respondent and found to be significantly correlated (R=0.78, 
P<0.001). Table 3 presents results of similar analyses per 
formed on the FIQ's subscales. 
TABLE 3 
Analysis of FIQ outcomes 












45-month Baseline- Baseline- Correlation’ 
Baseline EOS follow-up EOS follow-up R-value P-value 
S2.6 35.7 31.8 P<0.001 P - O.OO1 O.78 <0.001 
6.0 4.0 3.6 P < 0.01 P - O.OO1 O.78 <0.001 
7.7 6.O 4.53 P < 0.01 P - 0.001 O.69 <0.001 
7.9 6.2 S.O P < 0.01 P - O.OO1 O.S1 <0.01 
6.8 4.7 4.0 P < 0.01 P - O.OO1 O.49 O.O1 
4.0 1.8 2.6 P<0.001 P = 0.03 O.70 <0.001 
3.5 1.7 1.9 P<0.001 P - O.O1 O.63 <0.001 
*Correlation between changes from baseline at EOS and at follow-up 
Long-term improvement since EOS is significant at P = 0.02 
series of Likert Scale-based questions asked patients to 
report on symptom changes for tenderness, general pain, 
sleep, fatigue (energy), and depression/mood at both the end 
of study and currently. Patients were also asked to indicate 
how medicine use for both fibromyalgia pain and sleep had 
changed, and were asked a series of questions about their use 
of tricyclic antidepressants, selective serotonin reuptake 
inhibitors, pregabalin, dulloxetine and milnacipran since 
completing the study. Patients were also asked to indicate 
how their need to visit physicians or other caregivers spe 
cifically for fibromyalgia changed. 
0152. Of 39 mailed surveys, 25 were returned (64%). The 
average respondent age was 59 years (range 39-71). All 
respondents were female. The average time since comple 
tion of therapy was 45 months (range 31-60). 
0153. In terms of efficacy, the mean total FIQ score for 
the respondent group was 52.6 at baseline, 35.7 at end of 
0154 Table 4 provides a summary of patient responses 
for the level of improvement experienced in tenderness, 
pain, sleep, fatigue/energy, and depression/mood at end of 
study (EOS); their current condition for the same symptoms: 
and analysis of reported duration of response. 
0155 While there is an inherent bias in a survey method 
of this type, there does seem to be evidence of maintenance 
of improvement in fibromyalgia symptoms well beyond the 
end of the electrical stimulation treatment period. In addition 
to a Suggestion of long-term symptom improvement, there 
was also evidence of reduction in both fibromyalgia medi 
cation usage and health care resource utilization. Of those 
who had reported using pain medicines, 76% reported either 
reduced or eliminated medicine use for pain. Of those that 
have taken sleep medicines, 44% reported either reduced or 
eliminated medicine use for sleep. Finally, 71% of all 
respondents indicate reduced or eliminated need to see 
physicians or caregivers for fibromyalgia treatment. 
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0156 With regard to safety, patients were asked to report 
whether or not the therapy ever caused any pain or discom 
fort, and whether they experienced any side effects. No 
respondent reported experiencing any pain, discomfort or 
previously unreported side effects following completion of 
electrical stimulation therapy. 
TABLE 4 
Summary and analysis of patient responses for sympton improvement 
Fatigue Depression 




Much improved SO% 36%. 25%. 44% 32% 
Somewhat improved 38% 44%. 42%. 32% 20% 
No change 13% 20%. 33%. 20% 28% 
Got worse O% O% 0% 4% 4% 
Does not apply O% O%. 8% O% 16% 
Reported state of 
symptoms at 
time of follow-up 
More improved 20% 28%. 13%. 36% 32% 
Since EOS 
Same improvement 36% 36%. 46% 20% 28% 
as EOS 
Improved for a time, 40% 24%. 8% 24% 12% 
but returned 
Never changed got 4% 12%. 29%. 20% 12% 
WOSe 





Maintained to date 62% 75% 87% 749 80% 
More than two years 10% 0% 59 
1-2 years 59, 79% 59 
Less than one year 10% 0% 59 
Unknown duration 38% O% 6% 11% 20% 
End of study 
*Among long-term responders 
Incremental duration of effect was not evaluated for tenderness and depressionimood 
0157. Further, some of the survey’s symptom questions 
gave respondents the option to report any worsening of 
symptoms. No respondent reported worsening of tenderness, 
pain or sleep (0%). A worsening of fatigue was reported by 
one patient (4%) and worsening of depression was reported 
by one other (4%). 
0158. Further to this study, EEG coherence analysis was 
performed to evaluate functional neural network connectiv 
ity in patient participants. Coherence, which is a measure of 
the correlation of relative amplitude and phase between pairs 
of EEG signals, is an established measure of functional 
network connectivity, and is ideally Suited for providing 
temporally stable measures. Changes in EEG coherence in 
subjects who received the electrical stimulation treatment 
taught herein were compared to those Subjects who received 
sham. 
0159 Procedurally, eyes-closed resting EEG was col 
lected at 19 of the International 10-20 electrode sites for 
each subject at baseline and within one week of electrical 
stimulation therapy completion. To reduce coherence bias 
ing due to cortical volume conduction over short spatial 
distances, only non-neighboring electrode pairings (N=118) 
Nov. 24, 2016 
were analyzed. Fibromyalgia symptomatology was assessed 
with the FIQ and the Short Form-36 (SF-36). 
(0160 Baseline coherence was consistent between treat 
ment groups in 112 of the 118 possible electrode pairs (95%, 
P<0.05). Analysis found that group mean change from 
baseline coherence decreased 67% at end of study in the 
active treatment group, while a corresponding decrease of 
only 18% was seen in the sham group (P<0.001). In the 
active treatment group, 79 out of 118 electrode pairings 
achieved at least a 50% mean change from baseline 
response, compared to only 9 in the sham group (X2-86.3, 
P<0.001). Following active treatment using electrical stimu 
lation methods as taught herein, a number of significant 
positive correlations in both inter- and intra-hemispherical 
electrode pairings were found between change from baseline 
coherence and improvements in total FIQ score and SF-36 
domains. Further analysis showed improvements in FIO 
score and pain VAS scale were greatest in Subjects showing 
reductions in brain functional network connectivity based on 
changes in EEG coherence. 
Example 2 
0.161. A second clinical trial entitled “A Double-Blinded, 
Randomized, Sham-Controlled, Proof of Concept Phase 2 
Study Exploring the Safety and Efficacy of RINCE Tech 
nology for the Treatment of Patients with Fibromyalgia” 
(ClinicalTrials.gov registration NCT01825954), was con 
ducted at a single site on 45 evaluable fibromyalgia patients. 
Like the trial of Example 1, this trial also utilized a ran 
domized, blinded and sham controlled design. Fibromyalgia 
patient entry criteria were also similar to those used in 
Example 1. 
0162 The primary outcome measure for this study was 
the patients’ pain level as assessed by 0-100 mm visual 
analog scale (VAS) recordings. At each visit, the patient 
recorded their 24-hour recall pain score and at every other 
visit they also provided their seven-day recall pain score. 
Additional outcome measures included the patient global 
impression of change (PGIC), the revised Fibromyalgia 
Impact Questionnaire (FIO-R), the Jenkins sleep scale, the 
Beck depression inventory (BDI-II), the Multiple Ability 
Self-report Questionnaire (MASQ) and the Mental Clutter 
Scale (MCS). 
0163 The electrical stimulation signals applied to 
patients receiving active treatment included an electrical 
signal form configured for treating fibromyalgia or other 
central pain related neurological conditions as taught herein 
(i.e., "Signal 1), a composite electrical stimulation signal 
configured to provide long-term treatment of a neurological 
condition and provide analgesia for short-term pain relief 
(i.e., "Signal 2), and a signal configured only to provide 
analgesia for short-term pain relief (i.e., “Signal 3'). 
0164. Two separate groupings of therapeutic approach 
were studied. In a first grouping, 22 fibromyalgia patients 
were treated with either Signal 1 or a sham, essentially 
repeating the protocol of the trial of Example 1. Patients 
were randomized into three groups: Group 1A received 8 
weeks of Signal 1 treatment followed by 4 weeks of sham; 
Group 1B received 12 weeks of Signal 1 treatment; and 
Group 1C received 12 weeks of sham. Sham consisted of no 
signal delivery. The daily treatment delivery schedule and 
signal delivery timing on all patients was the same as that 
used in the trial of Example 1. 
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0165. In this first grouping of patients, primary outcomes 
analysis confirmed the therapeutic benefit which was also 
seen in the study of Example 1. Table 5 presents a summary 
of first grouping post-therapy to baseline differences in 
24-hour pain VAS, comparing the various treatment groups. 
The table entries represent group mean raw changes in pain 
VAS measures. 
TABLE 5 
Analysis of 24-hour pain VAS outcomes in first patient grouping 
Group 1B vs. Group 1A vs. Group 1B vs. 
Group 1C Group 1C Group 1A 
Change in Pain VAS -25.2 -19.9 -53 
PValue O.O23 OO67 O.64 
0166 As seen in Table 5, the reduction in pain as evi 
denced by change in 24-hour pain VAS was significantly 
greater in patients receiving 12 weeks of Signal 1 treatment 
versus those patients receiving sham (P=0.023). Patients 
receiving 8 weeks of Signal 1 had a greater reduction in pain 
over those receiving sham, but the difference missed sig 
nificance (P=0.067). The difference in pain reduction levels 
was not significant between patients receiving 12 weeks of 
Signal 1 versus those receiving 8 weeks of Signal 1 plus 4 
weeks of sham (P=0.64), although the longer application of 
Signal 1 did produce numerically Superior results. 
0167. In a second grouping, 23 additional fibromyalgia 
patients were treated with a combination of Signals 2 and 3. 
These patients were randomized into three groups: Group 
2A received 8 weeks of the composite Signal 2 treatment 
followed by 4 weeks of the short-term analgesic Signal 3: 
Group 2B received 12 weeks of Signal 2 only; and Group 2C 
received 12 weeks of Signal 3 only. The daily treatment 
delivery schedule and signal delivery timing on all patients 
was the same as that used in the trial of Example 1 and in 
the first grouping of patients in Example 2. 
0168 Table 6 presents a summary of second patient 
grouping post-therapy to baseline differences in 24-hour 
pain VAS, comparing the various treatment groups. The 
table entries represent group mean raw changes in pain VAS 
CaSUS. 
TABLE 6 
Analysis of 24-hour pain VAS outcomes in second patient grouping 
Group 2B vs. Group 2A vs. Group 2B vs. 
Group 2C Group 2C Group 2A 
Change in Pain VAS +26.4 +37.8 -11.4 
PValue -O.O17 -OOO1 0.27 
0169. While all patients in this second grouping received 
pain reduction over baseline as a result of stimulation signal 
therapy, the data of Table 6 show that those patients receiv 
ing 12 weeks of only the short-term analgesic Signal 3 had 
greater pain reduction over those patients receiving 12 
weeks of the composite Signal 2, with significance at 
P=0.017. Similarly, 12 weeks of short-term analgesic Signal 
3 produced significantly greater pain reduction over those 
patients receiving 8 weeks of the composite Signal 2 fol 
lowed by 4 weeks of the analgesic Signal 3 (P=0.001). Those 
patients receiving 12 weeks of only the composite signal had 
numerically greater pain reduction over those receiving 8 
Nov. 24, 2016 
weeks of the composite signal followed by 4 weeks of the 
analgesic signal, however the difference was not significant 
(P=0.27). 
0170 The results from the second grouping of patients 
Suggest that the use of a composite signal as taught herein 
can produce greater levels of immediate pain relief, as 
evidenced by 24-hour pain recall measures, over signals that 
are configured only for long-term treatment of fibromyalgia 
or other central pain related neurological conditions as 
taught herein. Further evidence of the mechanistic differ 
ences between the signals taught herein was gained by 
analyzing long-term patient outcomes. It would be expected 
that those patients who received only Signal 3, and who 
accordingly received the greatest level of pain reduction as 
evidenced by second grouping 24-hour pain VAS outcomes, 
would not have a corresponding long-term therapeutic 
effect. This would hypothetically be due to the lack of 
therapy with stimulation signals featuring components 
intended to provide long-term treatment of fibromyalgia or 
other central pain related neurological conditions, as taught 
herein. In Support of this, follow up data was gathered from 
a cohort of patients studied in Example 2. In the cohort, 
second grouping patients who received only Signal 3 did not 
maintain any long-term pain reduction benefit. Their follow 
up pain VAS scores were on average 14.8% worse than they 
were at baseline. In comparison, the cohort of patients who 
received any level of Signals 1 and 2 were still on average 
53.8% improved over baseline. The average time of follow 
up in these patients was approximately 4.5 months after 
cessation of therapy. 
0171 For both groupings, safety was assessed through 
routine collection of vital signs, routine collection of treat 
ment emergent adverse events, and review of neurocognitive 
functioning results (MASQ and MCS) and mood scores 
(BDI-II). A consistent finding in the Example 2 study was an 
extremely low rate of adverse events related to the therapy. 
Consistent with the study of Example 1, there were very few 
adverse event categories that seemed to correlate with the 
stimulation therapy. Out of the patients enrolled in Example 
2, there were no terminations for adverse events, and no 
serious adverse events. 97% of all adverse events were mild 
or moderate, and the vast majority appeared to be related to 
the underlying fibromyalgia condition. The only adverse 
event terms that may have been linked to therapy delivery 
were headache, Vertigo and scalp dermatitis related to the 
use of electrically conductive gel at the interface between 
the patient’s skin and the conductor's electrode. 
What is claimed is: 
1. A method of treating a neurological condition in a 
patient, the method comprising the step of applying an 
electrical stimulation from conductors to the patient’s head 
at a stimulation application site, the electrical stimulation 
comprising a composite electrical signal further comprising 
at least one signal form configured to provide long-term 
treatment of the neurological condition and at least one 
signal form configured to provide analgesia for short-term 
pain relief. 
2. The method of claim 1, in which the electrical stimu 
lation is subthreshold for detection by the patient. 
3. The method of claim 1, in which the at least one signal 
form configured to provide long-term treatment of the 
neurological condition and the at least one signal form 
configured to provide analgesia for short-term pain relief are 
applied simultaneously during a treatment application. 
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4. The method of claim 1, in which the at least one signal 
form configured to provide long-term treatment of the 
neurological condition and the at least one signal form 
configured to provide analgesia for short-term pain relief are 
applied at alternating times during a treatment application. 
5. The method of claim 1, in which the at least one signal 
form configured to provide long-term treatment of the 
neurological condition comprises an electrical signal con 
figured to treat an abnormal brain condition associated with 
the neurological condition. 
6. The method of claim 1, in which the at least one signal 
form configured to provide analgesia for short-term pain 
relief comprises an electrical signal configured to stimulate 
modulation of one or more neurotransmitters associated with 
analgesia. 
7. The method of claim 6, in which the modulation is 
selected from a group consisting of the release, expression, 
uptake, increased production, reduced production, inhibition 
or elimination of neurotransmitters. 
8. The method of claim 6, in which the neurotransmitters 
are selected from a group consisting of serotonin, norepi 
nephrine, glutamate, N-Methyl-D-aspartic acid, Substance 
P. gama-aminobutyric acid, various nucleotides or dop 
amine. 
9. The method of claim 1, in which the condition is 
selected from a group of neurological conditions consisting 
of but not limited to, fibromyalgia, central sensitivity, 
central pain, abnormal neural network connectivity, com 
plex regional pain syndrome, phantom pain, irritable bowel 
syndrome, temporomandibular disorder, myofascial pain 
syndrome, regional soft-tissue pain syndrome, neuropathic 
pain, osteoarthritis, back pain, post-operative pain, depres 
Sion, tension-type headaches or migraine headaches. 
10. The method of claim 1, in which the at least one signal 
form configured to provide long-term treatment of the 
neurological condition comprises a tissue transmission com 
ponent and a therapeutic component. 
11. The method of claim 10, in which the tissue trans 
mission component comprises a pulse train of frequency 
Sufficient to reduce tissue impedance between the conduc 
tors and the patient’s brain. 
12. The method of claim 11, in which the pulse train 
amplitude has a minimum value of 0 volts and a maximum 
value of 1 volt. 
13. The method of claim 11, in which the pulse train 
amplitude has a maximum value of 0.2 volts. 
14. The method of claim 11, in which the pulse train 
frequency is between 10,000 Hz and 20,000 Hz. 
15. The method of claim 11, in which the pulse train 
frequency is approximately 15,000 Hz. 
16. The method of claim 11, in which the pulse train is 
monopolar. 
17. The method of claim 11 in which the pulse train is 
pulse width modulated to create a variable duty cycle of on 
time and off time. 
18. The method of claim 17, in which the pulse train duty 
cycle is between 20% and 60%. 
19. The method of claim 17, in which the pulse train duty 
cycle is approximately 37.5%. 
20. The method of claim 11, in which the pulse train is 
amplitude modulated to create a waveshape comprising an 
amplitude envelope. 
21. The method of claim 20, in which the waveshape 
forms a therapeutic component. 
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22. The method of claim 20, in which the amplitude 
envelope forms a rectangular wave. 
23. The method of claim 20, in which the amplitude 
envelope forms a sinusoidal wave. 
24. The method of claim 20, in which the amplitude 
envelope forms a composite of multiple sinusoidal waves. 
25. The method of claim 24, in which the multiple 
sinusoidal waves have individual frequencies between 1 Hz 
and 30 HZ. 
26. The method of claim 20, in which the waveshape has 
a frequency between 1 Hz and 30 Hz. 
27. The method of claim 20, in which the waveshape has 
a frequency between 7 Hz and 12 Hz. 
28. The method of claim 20, in which the frequency of the 
waveshape changes as a function of stimulation delivery 
time. 
29. The method of claim 20, in which the waveshape is a 
rectangular wave with frequencies ranging from 7 Hz to 12 
HZ as a function of time. 
30. The method of claim 11, in which the pulse train has 
an amplitude with minimum value of 0 Volts and maximum 
value of 0.2 volts, a frequency of approximately 15,000 Hz 
and a duty cycle of approximately 37.5%. 
31. The method of claim 1, in which the electrical 
stimulation includes a sequencing step in which an electrical 
signal is applied in bursts for at least two burst periods with 
at least one rest period comprising no stimulation in between 
each pair of bursts. 
32. The method of claim 31, in which each burst period 
ranges in time from 1 second to 5 minutes. 
33. The method of claim 31, in which each burst period 
ranges in time from 30 seconds to 2 minutes. 
34. The method of claim 31, in which each rest period 
ranges in time from 1 second to 5 minutes. 
35. The method of claim 31, in which each rest period is 
60 seconds. 
36. The method of claim 31, further comprising measur 
ing the patient's EEG signal during the rest period. 
37. The method of claim 36, in which the EEG is 
measured at the stimulation application site. 
38. The method of claim 36, further comprising measur 
ing the patient's EEG signal for a period of rest prior to a 
first burst of stimulation signal. 
39. The method of claim 38, in which the period of rest 
prior to a first burst ranges in time from 1 second to 5 
minutes. 
40. The method of claim 38, in which the period of rest 
prior to a first burst is 3 minutes. 
41. The method of claim 36, further comprising measur 
ing the patient's EEG signal for a period of rest after a final 
burst of stimulation signal. 
42. The method of claim 41, in which the period of rest 
after a final burst ranges in time from 1 second to 5 minutes. 
43. The method of claim 41, in which the period of rest 
after a final burst is 3 minutes. 
44. The method of claim 31, wherein the sequencing step 
comprises a burst and rest time sequence consisting of a first 
three minute period of rest; 
applying a first burst of the electrical stimulation signal 
for 30 seconds; 
after applying the first burst, ceasing application of the 
electrical stimulation signal for a second period of rest 
lasting 60 seconds; 
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after the second period of rest, applying a second burst of 
electrical stimulation signal for 60 seconds; 
after applying the second burst, ceasing application of the 
electrical stimulation signal for a third period of rest 
lasting 60 seconds; 
after the third period of rest, applying a third burst of the 
electrical stimulation signal for 90 seconds; and 
after applying the third burst, ceasing application of the 
electrical stimulation signal for a fourth period of rest 
lasting three minutes. 
45. The method of claim 44, further comprising measur 
ing the patient's EEG signal during at least one period of 
rest. 
46. The method of claim 44, in which the stimulation 
burst comprises a pulse train, wherein said pulses have 
amplitude having a minimum value of 0 Volts, a maximum 
value of 0.2 volts, a frequency of approximately 15,000 Hz 
and a duty cycle of approximately 37.5%. 
47. The method of claim 44, in which the stimulation 
signal burst is amplitude modulated to form rectangular 
waveshapes, with said waveshapes having frequencies 
sweeping from 7 Hz to 12 Hz over approximately equal 
periods of time during the burst. 
48. The method of claim 31, further comprising perform 
ing the applying and sequencing steps repeatedly over a 
period of time. 
49. The method of claim 48, in which the applying and 
sequencing steps are performed at least once a day, with at 
least one day transpiring between applications. 
50. The method of claim 48, in which the applying and 
sequencing steps are performed twice in a calendar week, 
with two days transpiring between applications. 
51. The method of claim 48, in which the applying and 
sequencing steps are performed repeatedly over a period 
ranging from 8 to 12 consecutive weeks. 
52. The method of claim 48, in which the applying and 
sequencing steps are performed repeatedly over a period of 
12 consecutive weeks. 
53. The method of claim 48, in which the applying and 
sequencing steps are performed 24 times over the period of 
time. 
54. The method of claim 53, further comprising perform 
ing the applying and sequencing steps additional times to 
further treat the neurological condition and achieve more 
satisfactory alleviation of symptoms. 
55. The method of claim 1, in which the at least one signal 
form configured to provide analgesia for short-term pain 
relief comprises a periodic signal. 
56. The method of claim 55, in which the periodic signal 
is a pulse train. 
57. The method of claim 55, in which the periodic signal 
is a sinusoidal waveform. 
58. The method of claim 55, in which the periodic signal 
has frequencies between 1 Hz and 300 Hz. 
59. The method of claim 55, in which the periodic signal 
has frequencies between 50 Hz and 150 Hz. 
60. The method of claim 55, in which the periodic signal 
has a frequency of approximately 60 Hz. 
61. The method of claim 55, in which the periodic signal 
has a frequency of approximately 120 HZ. 
62. The method of claim 55, in which the periodic signal 
has amplitudes between -10 volts and +10 volts. 
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63. The method of claim 55, in which the periodic signal 
has minimum amplitude of -1 volts and maximum ampli 
tude of +1 volt. 
64. The method of claim 1, in which the at least one signal 
form configured to provide analgesia for short-term pain 
relief is applied during periods of rest time before or after 
bursts of at least one signal form configured to provide 
long-term treatment of a neurological condition. 
65. The method of claim 1, in which the at least one signal 
form configured to provide analgesia for short-term pain 
relief comprises a direct current (DC) signal. 
66. The method of claim 1, in which the applying step 
includes the step of placing conductors to create a current 
pathway through at least one portion of the patient’s brain. 
67. The method of claim 66, in which the portion of a 
brain is selected from a group consisting of the parietal 
lobes, somatosensory cortex, thalamus, prefrontal cortex, 
primary motor cortex, secondary motor cortex, insula or 
default mode network. 
68. The method of claim 66, wherein the conductors are 
placed proximate to the portion of the brain to be stimulated. 
69. The method of claim 66, in which the conductors are 
noninvasive. 
70. The method of claim 66, wherein the placing step 
comprises placing a first conductor proximate to the parietal 
lobes along the median plane, and a second conductor 
proximate to the right ear. 
71. The method of claim 66, wherein the placing step 
comprises placing a first conductor proximate to Interna 
tional 10-20 site PZ, and a second conductor proximate to the 
right ear lobe. 
72. The method of claim 1, wherein the applying step 
comprises applying electrical stimulation through conduc 
tors that create at least a first current pathway through at 
least a first portion of the patient’s brain for providing 
long-term treatment of the neurological condition, and at 
least a second current pathway through at least a second 
portion of the patient's brain for providing analgesia for 
short-term pain relief. 
73. The method of claim 72, wherein the conductors 
comprise at least two electrical leads placed proximate to the 
portion of the patient’s brain to be stimulated. 
74. The method of claim 73, in which the conductors are 
noninvasive. 
75. A method of treating a neurological condition in a 
patient, the method comprising: 
placing a first electrical lead on the patient's head proxi 
mate to International 10-20 site PZ; 
placing a second electrical lead proximate to the patients 
right ear lobe; 
applying a composite electrical stimulation signal com 
prising a signal configured to provide long-term treat 
ment of the neurological condition and a signal con 
figured to provide analgesia for short-term pain relief; 
wherein the signal configured to provide analgesia for 
short-term pain relief comprises a pulse train of both 60 
Hz positive pulses and 60 Hz negative pulses; 
wherein the positive pulses have a minimum amplitude of 
0 volts and a maximum amplitude of 0.5 volts: 
wherein the negative pulses have a maximum amplitude 
of 0 volts and a minimum amplitude of -0.5 volts: 
wherein the positive and negative pulses alternate and are 
equally spaced in time; 
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wherein the signal to provide long-term treatment of the 
neurological condition comprises a monopolar pulse 
train of frequency Sufficient to reduce tissue imped 
ance, 
wherein the pulse train amplitude has a minimum value of 
0 volts, a maximum value of 0.2 volts, a frequency of 
approximately 15,000 Hz, and a duty cycle of approxi 
mately 37.5%; 
wherein the pulse train is amplitude modulated to form a 
rectangular waveshape with frequencies ranging from 7 
HZ to 12 Hz, as a function of time; 
sequencing application of the electrical stimulation signal 
in a burst and rest time sequence consisting of 
a first burst comprising the signal configured to provide 
analgesia for short-term pain relief, lasting three min 
utes; 
a second burst comprising the signal configured to pro 
vide long-term treatment of the neurological condition, 
lasting 30 seconds, with frequencies Sweeping from 7 
HZ to 12 Hz over approximately equal periods of time 
during the burst; 
a third burst comprising the signal configured to provide 
analgesia for short-term pain relief, lasting 60 seconds; 
a fourth burst comprising the signal configured to provide 
long-term treatment of the neurological condition, last 
ing 60 seconds, with frequencies Sweeping from 7 HZ 
to 12 HZ over approximately equal periods of time 
during the burst; 
a fifth burst comprising the signal configured to provide 
analgesia for short-term pain relief, lasting 60 seconds; 
a sixth burst comprising the signal configured to provide 
long-term treatment of the neurological condition, last 
ing 90 seconds, with frequencies sweeping from 7 Hz 
to 12 HZ over approximately equal periods of time 
during the burst; and 
a seventh burst comprising the signal configured to pro 
vide analgesia for short-term pain relief, lasting three 
minutes; 
wherein the electrical stimulation is conducted along a 
current pathway created between the first electrical lead 
placed proximate to International 10-20 site PZ, and the 
second electrical lead placed proximate to the right ear 
lobe: 
performing the placing, applying and sequencing steps 
twice in a calendar week, with at least one day trans 
piring between treatment applications, over a period of 
12 consecutive weeks. 
76. An electrical stimulation apparatus comprising an 
electrical signal generator adapted to provide an electrical 
signal form configured to provide long-term treatment of a 
neurological condition and to provide an electrical signal 
form configured to provide analgesia for short-term pain 
relief. 
77. The apparatus of claim 76, in which the electrical 
signal generator further comprises at least one microcon 
troller configured to generate composite signal waveforms 
and coupled to at least one signal conditioning circuit 
configured to transform the composite signal waveforms 
into stimulation signals. 
78. The apparatus of claim 77, in which the at least one 
signal conditioning circuit comprises an amplifier circuit. 
79. The apparatus of claim 76, further comprising any one 
or more circuit elements selected from the group of circuit 
elements consisting of an EEG amplifier configured to 
20 
Nov. 24, 2016 
measure EEG signals, a filter circuit configured to reduce 
electrical noise in EEG signals, an isolation amplifier con 
figured to protect human Subjects, an analog-to-digital inter 
face configured to convert analog EEG signals to digital 
signals, and an isolated power Supply configured to provide 
circuit power and human Subject protection. 
80. The apparatus of claim 76, further comprising at least 
two electrical leads for providing a composite stimulation 
signal current pathway between the electrical signal genera 
tor and a tissue to be stimulated. 
81. The apparatus of claim 76, further comprising a user 
interface. 
82. The apparatus of claim 81, further comprising a 
Software graphic user interface which provides user guid 
ance for providing a composite stimulation signal. 
83. A method for treating a neurological condition in a 
patient, the method comprising: applying an electrical 
stimulation signal from conductors to the patient’s head at a 
stimulation application site, wherein the electrical stimula 
tion signal comprises a tissue transmission component and a 
therapeutic component; and sequencing the electrical stimu 
lation signal in bursts for at least two burst periods with at 
least one rest period comprising no stimulation in between 
each pair of bursts. 
84. The method of claim 83, in which the electrical 
stimulation signal is subthreshold for detection by the 
patient. 
85. The method of claim 83, in which the tissue trans 
mission component comprises a pulse train of frequency 
Sufficient to reduce tissue impedance between the conduc 
tors and the patient’s brain. 
86. The method of claim 85, in which the pulse train 
amplitude has a minimum value of 0 volts and a maximum 
value of 1 volt. 
87. The method of claim 85, in which the pulse train 
amplitude has a maximum value of 0.2 volts. 
88. The method of claim 85, in which the pulse train 
frequency is between 10,000 Hz and 20,000 Hz. 
89. The method of claim 85, in which the pulse train 
frequency is approximately 15,000 Hz. 
90. The method of claim 85, in which the pulse train is 
monopolar. 
91. The method of claim 85, in which the pulse train is 
pulse width modulated to create a variable duty cycle of on 
time and off time. 
92. The method of claim 91, in which the pulse train duty 
cycle is between 20% and 60%. 
93. The method of claim 91, in which the pulse train duty 
cycle is approximately 37.5%. 
94. The method of claim 85, in which the pulse train is 
amplitude modulated to create a waveshape comprising an 
amplitude envelope. 
95. The method of claim 94, in which the waveshape 
forms a therapeutic component. 
96. The method of claim 94, in which the amplitude 
envelope forms a rectangular wave. 
97. The method of claim 94, in which the amplitude 
envelope forms a sinusoidal wave. 
98. The method of claim 94, in which the amplitude 
envelope forms a composite of multiple sinusoidal waves. 
99. The method of claim 98, in which the multiple 
sinusoidal waves have individual frequencies between 1 Hz 
and 30 HZ. 
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100. The method of claim 94, in which the waveshape has 
a frequency between 1 Hz and 30 Hz. 
101. The method of claim 94, in which the waveshape has 
a frequency between 7 Hz and 12 Hz. 
102. The method of claim 94, in which the frequency of 
the waveshape changes as a function of stimulation delivery 
time. 
103. The method of claim 94, in which the waveshape is 
a rectangular wave with frequencies ranging from 7 Hz to 12 
HZ as a function of time. 
104. The method of claim 85, in which the pulse train has 
an amplitude with minimum value of 0 Volts and maximum 
value of 0.2 volts, a frequency of approximately 15,000 Hz 
and a duty cycle of approximately 37.5%. 
105. The method of claim 83, in which each burst period 
ranges in time from 1 second to 5 minutes. 
106. The method of claim 83, in which each burst period 
ranges in time from 30 seconds to 2 minutes. 
107. The method of claim 83, in which each rest period 
ranges in time from 1 second to 5 minutes. 
108. The method of claim 83, in which each rest period is 
60 seconds. 
109. The method of claim 83, further comprising mea 
Suring the patient’s electroencephalogram (EEG) signal dur 
ing the rest period. 
110. The method of claim 109, in which the EEG is 
measured at the stimulation application site. 
111. The method of claim 109, further comprising mea 
suring the patient's EEG signal for a period of rest prior to 
a first burst of stimulation signal. 
112. The method of claim 111, in which the period of rest 
prior to a first burst ranges in time from 1 second to 5 
minutes. 
113. The method of claim 111, in which the period of rest 
prior to a first burst is 3 minutes. 
114. The method of claim 109, further comprising mea 
suring the patient's EEG signal for a period of rest after a 
final burst of Stimulation signal. 
115. The method of claim 114, in which the period of rest 
after a final burst ranges in time from 1 second to 5 minutes. 
116. The method of claim 114, in which the period of rest 
after a final burst is 3 minutes. 
117. The method of claim 83, wherein the sequencing step 
comprises a burst and rest time sequence consisting of 
a first three minute period of rest; 
applying a first burst of the electrical stimulation signal 
for 30 seconds; 
after applying the first burst, ceasing application of the 
electrical stimulation signal for a second period of rest 
lasting 60 seconds; 
after the second period of rest, applying a second burst of 
the electrical stimulation signal for 60 seconds; 
after applying the second burst, ceasing application of the 
electrical stimulation signal for a third period of rest 
lasting 60 seconds; 
after the third period of rest, applying a third burst of the 
electrical stimulation signal for 90 seconds; and 
after applying the third burst, ceasing application of the 
electrical stimulation signal for a fourth period of rest 
lasting three minutes. 
118. The method of claim 117, in which the stimulation 
burst comprises a pulse train, wherein said pulses have 
amplitude having a minimum value of 0 Volts, a maximum 
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value of 0.2 volts, a frequency of approximately 15,000 Hz 
and a duty cycle of approximately 37.5%. 
119. The method of claim 117, in which the stimulation 
signal burst is amplitude modulated to form rectangular 
waveshapes, with said waveshapes having frequencies 
sweeping from 7 Hz to 12 Hz over approximately equal 
periods of time during the burst. 
120. The method of claim 83, in which the applying step 
includes the step of placing conductors to create a current 
pathway through at least one portion of the patient’s brain. 
121. The method of claim 120, in which the portion of a 
brain is selected from a group consisting of the parietal 
lobes, somatosensory cortex, thalamus, prefrontal cortex, 
primary motor cortex, secondary motor cortex, insula or 
default mode network. 
122. The method of claim 120, wherein the conductors are 
placed proximate to the portion of the brain to be stimulated. 
123. The method of claim 120, wherein the placing step 
comprises placing a first conductor proximate to the parietal 
lobes along the median plane, and a second conductor 
proximate to the right ear. 
124. The method of claim 120, wherein the placing step 
comprises placing a first conductor proximate to Interna 
tional 10-20 site PZ, and a second conductor proximate to the 
right ear lobe. 
125. The method of claim 83, in which the conductors are 
noninvasive. 
126. The method of claim 83, further comprising per 
forming the applying and sequencing steps repeatedly over 
a period of time. 
127. The method of claim 126, in which the applying and 
sequencing steps are performed at least once a day, with at 
least one day transpiring between applications. 
128. The method of claim 126, in which the applying and 
sequencing steps are performed twice in a calendar week, 
with two days transpiring between applications. 
129. The method of claim 126, in which the applying and 
sequencing steps are performed repeatedly over a period 
ranging from 8 to 24 consecutive weeks. 
130. The method of claim 126, in which the applying and 
sequencing steps are performed repeatedly over a period of 
12 consecutive weeks. 
131. The method of claim 126, in which the applying and 
sequencing steps are performed 24 times over the period of 
time. 
132. The method of claim 131, further comprising per 
forming the applying and sequencing steps additional times 
to further treat the neurological condition and achieve more 
satisfactory alleviation of symptoms. 
133. The method of claim 83, in which the neurological 
condition is selected from a group consisting of hyperalge 
sia, central pain, central sensitivity, chronic pain, abnormal 
brain network connectivity, neuropathic pain, central pain 
arising from chronic osteoarthritis, central pain arising from 
chronic back pain, chronic headache, migraine headache or 
depression. 
134. A method of treating a neurological condition in a 
patient, the method comprising: 
placing a first conductor on the patient's head proximate 
to International 10-20 site PZ; 
placing a second conductor proximate to the patients 
right ear lobe; 
applying an electrical stimulation signal between the first 
and second conductors, the electrical stimulation signal 
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comprising a tissue transmission component further 
comprising a monopolar pulse train of frequency Suf 
ficient to reduce tissue impedance between the conduc 
tors and the patient’s brain; 
wherein the pulse train amplitude has a minimum value of 
0 volts, a maximum value of 0.2 volts, a frequency of 
approximately 15,000 Hz, and a duty cycle of approxi 
mately 37.5%; 
wherein the pulse train is amplitude modulated to form a 
rectangular waveshape with frequencies ranging from 7 
HZ to 12 Hz, as a function of time; 
sequencing application of the electrical stimulation signal 
in a burst and rest time sequence consisting of 
a first three minute period of rest; 
after the first period of rest, applying a first burst of the 
electrical stimulation signal for 30 seconds, with 
frequencies sweeping from 7 Hz to 12 Hz over 
approximately equal periods of time during the burst; 
after applying the first burst, ceasing application of the 
electrical stimulation signal for a second period of 
rest lasting 60 seconds; 
after the second period of rest, applying a second burst 
of the electrical stimulation signal for 60 seconds, 
with frequencies sweeping from 7 Hz to 12 Hz over 
approximately equal periods of time during the burst; 
after applying the second burst, ceasing application of 
the electrical stimulation signal for a third period of 
rest lasting 60 seconds; 
after the third period of rest, applying a third burst of 
the electrical stimulation signal for 90 seconds, with 
frequencies sweeping from 7 Hz to 12 Hz over 
approximately equal periods of time during the burst; 
and 
after applying the third burst, ceasing application of the 
electrical stimulation signal for a fourth period of 
rest lasting three minutes; 
performing the placing, applying and sequencing steps 
twice in a calendar week, with at least one day trans 
piring between treatment applications, over a period of 
12 consecutive weeks. 
135. A method for treating fibromyalgia in a patient, the 
method comprising: applying an electrical stimulation signal 
from conductors to the patient's head at a stimulation 
application site, wherein the electrical stimulation signal 
comprises a tissue transmission component and a therapeutic 
component; and sequencing the electrical stimulation signal 
in bursts for at least two burst periods with at least one rest 
period comprising no stimulation in between each pair of 
bursts. 
136. The method of claim 135, in which the electrical 
stimulation signal is subthreshold for detection by the 
patient. 
137. The method of claim 135, in which the tissue 
transmission component comprises a pulse train of fre 
quency Sufficient to reduce tissue impedance between the 
conductors and the patient’s brain. 
138. The method of claim 137, in which the pulse train 
amplitude has a minimum value of 0 volts and a maximum 
value of 1 volt. 
139. The method of claim 137, in which the pulse train 
amplitude has a maximum value of 0.2 volts. 
140. The method of claim 137, in which the pulse train 
frequency is between 10,000 Hz and 20,000 Hz. 
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141. The method of claim 137, in which the pulse train 
frequency is approximately 15,000 Hz. 
142. The method of claim 137, in which the pulse train is 
monopolar. 
143. The method of claim 137, in which the pulse train is 
pulse width modulated to create a variable duty cycle of on 
time and off time. 
144. The method of claim 143, in which the pulse train 
duty cycle is between 20% and 60%. 
145. The method of claim 143, in which the pulse train 
duty cycle is approximately 37.5%. 
146. The method of claim 143, in which the pulse train is 
amplitude modulated to create a waveshape comprising an 
amplitude envelope. 
147. The method of claim 146, in which the waveshape 
forms a therapeutic component. 
148. The method of claim 146, in which the amplitude 
envelope forms a rectangular wave. 
149. The method of claim 146, in which the amplitude 
envelope forms a sinusoidal wave. 
150. The method of claim 146, in which the amplitude 
envelope forms a composite of multiple sinusoidal waves. 
151. The method of claim 150, in which the multiple 
sinusoidal waves have individual frequencies between 1 Hz 
and 30 HZ. 
152. The method of claim 146, in which the waveshape 
has a frequency between 1 Hz and 30 Hz. 
153. The method of claim 146, in which the waveshape 
has a frequency between 7 Hz and 12 Hz. 
154. The method of claim 146, in which the frequency of 
the waveshape changes as a function of stimulation delivery 
time. 
155. The method of claim 146, in which the waveshape is 
a rectangular wave with frequencies ranging from 7 Hz to 12 
HZ as a function of time. 
156. The method of claim 137, in which the pulse train 
has an amplitude with minimum value of 0 volts and 
maximum value of 0.2 volts, a frequency of approximately 
15,000 Hz, and a duty cycle of approximately 37.5%. 
157. The method of claim 135, in which each burst period 
ranges in time from 1 second to 5 minutes. 
158. The method of claim 135, in which each burst period 
ranges in time from 30 seconds to 2 minutes. 
159. The method of claim 135, in which each rest period 
ranges in time from 1 second to 5 minutes. 
160. The method of claim 135, in which each rest period 
is 60 seconds. 
161. The method of claim 135, further comprising mea 
Suring the patient’s electroencephalogram (EEG) signal dur 
ing the rest period. 
162. The method of claim 161, in which the EEG is 
measured at the stimulation application site. 
163. The method of claim 161, further comprising mea 
suring the patient's EEG signal for a period of rest prior to 
a first burst of stimulation signal. 
164. The method of claim 163, in which the period of rest 
prior to a first burst ranges in time from 1 second to 5 
minutes. 
165. The method of claim 163, in which the period of rest 
prior to a first burst is 3 minutes. 
166. The method of claim 161, further comprising mea 
suring the patient's EEG signal for a period of rest after a 
final burst of Stimulation signal. 
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167. The method of claim 166, in which the period of rest 
after a final burst ranges in time from 1 second to 5 minutes. 
168. The method of claim 166, in which the period of rest 
after a final burst is 3 minutes. 
169. The method of claim 135, wherein the sequencing 
step comprises a burst and rest time sequence consisting of 
a first three minute period of rest; 
applying a first burst of the electrical stimulation signal 
for 30 seconds; 
after applying the first burst, ceasing application of the 
electrical stimulation signal for a second period of rest 
lasting 60 seconds; 
after the second period of rest, applying a second burst of 
the electrical stimulation signal for 60 seconds; 
after applying the second burst, ceasing application of the 
electrical stimulation signal for a third period of rest 
lasting 60 seconds; 
after the third period of rest, applying a third burst of the 
electrical stimulation signal for 90 seconds; and 
after applying the third burst, ceasing application of the 
electrical stimulation signal for a fourth period of rest 
lasting three minutes. 
170. The method of claim 169, in which the stimulation 
burst comprises a pulse train, wherein said pulses have 
amplitude having a minimum value of 0 Volts, a maximum 
value of 0.2 volts, a frequency of approximately 15,000 Hz 
and a duty cycle of approximately 37.5%. 
171. The method of claim 169, in which the stimulation 
signal burst is amplitude modulated to form rectangular 
waveshapes, with said waveshapes having frequencies 
sweeping from 7 Hz to 12 Hz over approximately equal 
periods of time during the burst. 
172. The method of claim 135, in which the applying step 
includes the step of placing conductors to create a current 
pathway through at least one portion of the patient’s brain. 
173. The method of claim 172, in which the portion of a 
brain is selected from a group consisting of the parietal 
lobes, somatosensory cortex, thalamus, prefrontal cortex, 
primary motor cortex, secondary motor cortex, insula or 
default mode network. 
174. The method of claim 172, wherein the conductors are 
placed proximate to the portion of the brain to be stimulated. 
175. The method of claim 172, wherein the placing step 
comprises placing a first conductor proximate to the parietal 
lobes along the median plane, and a second conductor 
proximate to the right ear. 
176. The method of claim 172, wherein the placing step 
comprises placing a first conductor proximate to Interna 
tional 10-20 site PZ, and a second conductor proximate to the 
right ear lobe. 
177. The method of claim 135, in which the conductors 
are noninvasive. 
178. The method of claim 135, further comprising per 
forming the applying and sequencing steps repeatedly over 
a period of time. 
179. The method of claim 178, in which the applying and 
sequencing steps are performed at least once a day, with at 
least one day transpiring between applications. 
180. The method of claim 178, in which the applying and 
sequencing steps are performed twice in a calendar week, 
with two days transpiring between applications. 
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181. The method of claim 178, in which the applying and 
sequencing steps are performed repeatedly over a period 
ranging from 8 to 24 consecutive weeks. 
182. The method of claim 178, in which the applying and 
sequencing steps are performed repeatedly over a period of 
12 consecutive weeks. 
183. The method of claim 178, in which the applying and 
sequencing steps are performed 24 times over the period of 
time. 
184. The method of claim 183, further comprising per 
forming the applying and sequencing steps additional times 
to further treat the fibromyalgia and achieve more satisfac 
tory alleviation of symptoms. 
185. A method of treating fibromyalgia in a patient, the 
method comprising: 
placing a first conductor on the patient's head proximate 
to International 10-20 site PZ; 
placing a second conductor proximate to the patients 
right ear lobe; 
applying an electrical stimulation signal between the first 
and second conductors, the electrical stimulation signal 
comprising a tissue transmission component further 
comprising a monopolar pulse train of frequency Suf 
ficient to reduce tissue impedance between the conduc 
tors and the patient’s brain; 
wherein the pulse train amplitude has a minimum value of 
0 volts, a maximum value of 0.2 volts, a frequency of 
approximately 15,000 Hz, and a duty cycle of approxi 
mately 37.5%; 
wherein the pulse train is amplitude modulated to form a 
rectangular waveshape with frequencies ranging from 7 
HZ to 12 Hz, as a function of time; 
sequencing application of the electrical stimulation signal 
in a burst and rest time sequence consisting of 
a first three minute period of rest; 
after the first period of rest, applying a first burst of the 
electrical stimulation signal for 30 seconds, with 
frequencies sweeping from 7 Hz to 12 Hz over 
approximately equal periods of time during the burst; 
after applying the first burst, ceasing application of the 
electrical stimulation signal for a second period of 
rest lasting 60 seconds; 
after the second period of rest, applying a second burst 
of the electrical stimulation signal for 60 seconds, 
with frequencies sweeping from 7 Hz to 12 Hz over 
approximately equal periods of time during the burst; 
after applying the second burst, ceasing application of 
the electrical stimulation signal for a third period of 
rest lasting 60 seconds; 
after the third period of rest, applying a third burst of 
the electrical stimulation signal for 90 seconds, with 
frequencies sweeping from 7 Hz to 12 Hz over 
approximately equal periods of time during the burst; 
and 
after applying the third burst, ceasing application of the 
electrical stimulation signal for a fourth period of 
rest lasting three minutes; 
performing the placing, applying and sequencing steps 
twice in a calendar week, with at least one day trans 
piring between treatment applications, over a period of 
12 consecutive weeks. 
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